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Abstract 
Allogeneic hematopoietic stem cell transplantation (aHSCT) is the only curative option 
for many otherwise incurable diseases such as hematopoietic malignancies and genetic 
disorders. However, chronic Graft-Versus-Host Disease (cGVHD) is commonly seen in 
long-term survivors of aHSCT and has become the leading cause of non-relapse 
mortality. Little improvement has been made to the clinical management of cGVHD in 
several decades, which relies on systemic immunosuppression that is often associated 
with complications.  This is expected to change with updated understanding of cGVHD 
pathogenesis brought by the development of several new murine models. It is broadly 
accepted that cGVHD development undergoes 3 biological phases: 1. Tissue damage and 
innate immune activation leading to donor T cells activation, 2. Compromised immune 
tolerance and disturbed immune reconstitution leading to autoimmunity, 3. Aberrant 
tissue repair and autoantibody deposition leading to activation of pro-fibrotic pathways. 
In this study, we sought to explore approaches to block cGVHD through the inhibition of 
each biological phase of cGVHD. First, we demonstrated that donor T cells allo 
responses is dependent on a Ca2+ dependent inositol trisphosphate 3-kinase B (Itpkb) – an 
enzyme downstream of T cell receptor activation and functions through regulation of 
intracellular Ca2+ level. Blocking Itpkb by genetic ablation or pharmacological inhibition 
completely blocked or attenuated cGVHD in 2 different cGVHD models with 
complementary clinical manifestations. Second, we demonstrated that the deregulated 
immune balance could be restored by infusion of a potent regulatory cell population, the 
invariant Nature Killer T cells (iNKTs). iNKT infusion expanded Treg population in a 
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CXCR5 and IL-4 dependent manner and restored the T follicular helper/regulatory 
balance. Third, we demonstrated that pulmonary fibrosis as a result of end organ damage 
during cGVHD could be reversed by Pirfenidone, a drug approved by FDA for idiopathic 
pulmonary fibrosis. The effect was associated with reduced macrophage infiltration and 
TGF-β production. Finally, to identify cGVHD biomarkers for cGVHD early diagnosis 
and treatment, we conducted full spectrum proteomic analysis of serum samples from the 
well-established murine multi-organ system cGVHD model with bronchiolitis obliterans 
syndrome (BOS). Using high throughput, discovery-based Mass Spectrometry (MS) 
technique, we identified 4 potential biomarkers of cGVHD, of which CCL15 proved 
druggable and was verified in highly characterized and previously reported patient 
cohorts. Collectively, this work identifies several potential therapeutic targets and a 
verified biomarker that may improve cGVHD clinical management and diagnosis. In 
addition, this work provides new insights into cGVHD pathogenesis.    
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Chapter 1 Introduction  
		 2	
1.1 History of bone marrow transplantation and graft versus host disease  
 
The origin of stem cell transplantation dates backed to 1950s and was closely linked with 
the development of techniques using radioactive materials. During the 1910s and 20s, 
radioactive compounds were becoming increasingly used in the workplace in a way that 
no protection was taken into consideration and used. Consequently, a higher incidence of 
leukemia and other diseases was observed in those workers. However, only a small 
number of people had been affected by the radiation and the cause of their deaths only 
became apparent much later after their death. Thus, doctors could not generate useful 
conclusions regarding why the diseases happen and how to prevent them. Later, the rapid 
progress on radiation research had ultimately led to the invention of nuclear bomb which 
caused thousands of death in Japan during world war II, not only from the blast of bomb 
explosion, but also from the intense nuclear radiation. Doctors and researchers had the 
unfortunate opportunity to observe tens of thousands of patients and gain a more 
comprehensive understanding of how “radiation sickness” progressed in humans and 
which regions of the body were most affected. Doctors had gradually realized that 
radiation exposures of the bones cause the loss of blood cells. This observation triggered 
the desire to restore bone marrow function in aplasia caused by radiation exposure in 
human.  
  
At the same time, researchers were using animal models to understand the effect of 
radiation on health and disease. In a pivotal experiment, Jacobsen (1949) and colleagues 
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cite ref in bibliography documented that hematopoiesis was preserved in mice after lethal 
irradiation if the spleen was shielded. He further demonstrated a similar protective effect 
by shielding the femur, establishing that bone marrow and spleen are organs to produce 
and/or store blood cells. Lorenz (1951) and colleagues1 later demonstrated that mice 
recovered from radiation injury when infused with bone marrow after a lethal dose of 
radiation. It was uncertain that whether the protective effect is from humoral or cellular 
factors. However, subsequent work established bone marrow as the source of "cellular 
elements" required for hematopoietic recovery. Ford et al2 (1956) reported that lethally 
irradiated mice were protected by a subsequent marrow infusion, and Nowell et al3 
(1956) demonstrated the presence of rat cells in the marrow of irradiated mice that are 
protected against lethal irradiation by rat marrow.  These studies established that bone 
marrow contains cells that have the ability of making blood cells, what we now know as 
the hematopoietic stem cells.  
 
Accumulating studies in rodent models of bone marrow transplantation led to initial 
attempts at translating the discovery into the clinic. In 1957, Thomas ED reported 
temporary recovery after intravenous infusion of BM in patients receiving radiation and 
chemotherapy4. Later, he demonstrated hematopoietic recovery after autologous BM 
transplantation between identical twins following high dose radiation (1000 cGray)5. 
However, most bone marrow transplantations at that time were before the knowledge of 
histocompatibility antigen and HLA genotyping, and the grafts were mostly from siblings 
or un-related donors. Not surprisingly, almost all the early clinical transplantation efforts 
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in the late 1950s and early 1960s failed. In many cases the graft was rejected, and, if the 
graft was accepted, patients developed severe “secondary disease” that led to death. 
Billingham6 (1959) and colleagues described an immune reaction characterized by rash, 
diarrhea after bone marrow infusion, which they called "Runt disease" or what is now 
known as Graft Versus Host Disease (GVHD), the result of an immune reaction of the 
engrafted lymphoid cells against the tissues of the host. Thus, the idea of BMT was 
almost abandoned by the doctors at that time. However, research on animals continued 
and researchers realized that procedures based on inbred mice cannot directly transfer to 
human. Research done on outbred animals such as dogs and primates eventually relighted 
the hope of using BMT to treat diseases. New methods of host immunosuppression and 
myelosuppression involving chemotherapeutic agents such as cyclophosphamide and 
busulphan, respectively, were developed. Techniques for isolating the grafts from 
peripheral blood and bone marrow were improved. Agents to combat graft rejection were 
further refined in the dog transplantation model.  
 
In 1968 in Minnesota, the first successful allogeneic transplant was performed7. The 
donor was a sibling of the patient. By this time, it was known that genetic matching 
(known as HLA) is the key to a successful transplant. A sibling is the most likely person 
to be a good match as they inherited DNA from the same parents and can be fully 
matched for HLA antigens. Having a closely matched donor can help reduce the 
possibility of developing GVHD. However, many people do not have a sibling who is 
HLA-matched. In this situation, an HLA-matched unrelated donor can be used. The first 
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successful unrelated donor transplant took place in 1973 in New York when a young boy 
with a genetic immunodeficiency disorder received multiple marrow transplants from a 
donor identified as a match through a blood bank in Denmark8. In 1986, the National 
Bone Marrow Donor Registry was federally funded in Seattle. Stem cell transplantation 
has been increasingly performed each year world wide for a long list of different 
diseases9–13. However, GVHD, especially cGVHD continues to a significant burden for 
long-term survivors of transplant patients14,15  
 
1.2 Murines models of cGVHD 
Mice are the most widely used animals for many areas of biomedical researches. 
Compared with other research animals that are being used, mice have several 
advantages16. First, large number of mice with same genetic background can be 
maintained in similar environment in relatively low cost. This is desirable for getting 
solid repeatable conclusions. Second, gene-editing techniques on mice are more mature 
than other research animal species. Thus the use of genetically modified mice has been 
promoting researches in gene function study and facilitating certain assays (luciferase 
expressing mice).  Third, the handling of mice is relatively easier than other animals so 
that lab personals can gain the ability of working on mice quickly. Studies conducted on 
mice have identified many factors that are responsible for the success or failure of a 
BMT. Murine model of cGVHD are generally categorized into the following types based 
on the phenotypes and underlying immunologic mechanisms: 1. Autoimmunity driven by 
B cell mediated autoantibody production leading to systemic lupus erythematosus (SLE) 
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like disease – the SLE model. 2. Pro-fibrotic pathways activation that result in 
sclerodermatous like disease - the Scl model. 3. Germinal center response driven 
systemic fibrosis with bronchiolitis obliterans (BO)- the BO model.   
 
The SLE models mimic the autoimmune features of human cGVHD and have been useful 
in study both human lupus and cGVHD. In the SLE-cGVHD models, immune cells from 
MHC-mismatched donors are adoptively transferred to recipients. In a typical setting, 
parent peripheral immune cells are infused to non-irradiated F1 recipients. The resulting 
phenotype is predominated by the generation of autoantibodies directed against dsDNA, 
ssDNA and chromatin and immune-complex glomerulonephritis17–20. Involvement of 
lung has also been reported in several studies21.  Mechanism that leads to autoantibody 
production is described as CD4 T cells activation by B cells as antigen presenting cell 
(APC) and B cell activation and maturation with the help of CD4 T helper cells. The role 
of CD8 T cells is much smaller in the pathogenesis of these models. Although the SLE 
models have contributed to the understanding of cGVHD pathogenesis, especially in the 
establishment the roles of B cells and autoantibodies, there are many shortcomings. For 
example, the use of peripheral blood cells rather than stem cells and the lack of 
conditioning regimen on recipients are obviously not mimicking human BMT, while 
these factors can have major effects on the outcome of BMT. In addition, although these 
models have the autoimmune features seen in cGVHD patients, the specificities of 
autoantibodies identified in human patients are a lot more heterogeneous, suggesting the 
more complex immunological mechanism are taking place in human.  
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The Scl model uses donor and recipient combination that differs only at the minor 
histocompatibility loci but is MHC matched. The most common strain combination is 
B10.D2 (H2d) into Balb/c (H2d) model. In a typical experiment, Balb/c recipients are 
conditioned by irradiation followed by transplanting B10.D2 bone marrow and un-
fractioned splenocytes or purified T cells. Fur loss, skin thickening and scleroderma can 
be noticed 3-week post-BMT. Weight loss that is proportional to donor T cell dose 
usually accompanies skin disease, suggesting a systemic effect of the disease. Indeed, 
fibrotic change in the liver, lung and gastrointestinal track are also noticed22.  
 
Histologically, disease mice loss dermal fat and hair follicles are destroyed22. Different 
from the skin lesion caused by acute GVHD, skin thickening, but not cytotoxic epithelial 
injury, is the predominant manifestation of Scl GVHD, as the epidermis is intact, without 
significant numbers of apoptotic keratinocytes, a marker of cytotoxic injury23. Collagen 
deposition is increased and this is proceeded by influx of heterogeneous infiltrates of both 
lymphocytes and mononuclear cells including macrophages that express the M2 
macrophage marker CD20624.  
 
Different from the SLE models that do not involve conditioning regimen, tissue damaged 
caused by pre-transplant conditioning plays an important role in the pathogenesis in the 
Scl models. Usually, recipients are irradiated by lethal dose of X-ray (700-1100 cGray). 
Damaged tissues release chemokines such as CCL2, CCL3 and CCL5 that recruit innate 
immune cells such as macrophages into the damage sites. At the same time damage 
		 8	
associated molecular patterns (DAMPs) released from damaged tissue activates innate 
immune cells and donor T cells, result in the release of pro-inflammatory cytokines such 
as IFN-γ, IL-1β and so on that further aggravates tissue damage.  Macrophages play an 
important role in the development of skin scleroderma in these models. Markers of 
macrophage activation are increased after BMT, such as scavenger receptors MARCO 
and [spell out ScR-A] type I and II. MHCII molecules that are increased during antigen 
presentation are also increased during skin scleroderma25. In 2 different MHC 
mismatched models  
(Colony Stimulating Factor (CSF) mobilized Balb/c graft to B6 recipient and B6 graft to 
B6D2F1 recipient) that also develop skin scleroderma as the major manifestation, 
Alexander et al proved that skin scleroderma is mediated by infiltrating macrophages that 
are donor derived and dependent on CSF-CSFR signaling M2 macrophages. Treatment 
with anti–CSF-1R monoclonal antibody reduced macrophage infiltration and pathology 
score26.  
The Scl-cGVHD models share many phenotypic features with the sclerodermatous form 
of human cGVHD, which is generally refractory to standard therapy.  The incidence of 
sclerodermas cGVHD is estimated to be 3-10%, although both its incidence and severity 
could be increased as a result of more frequent unrelated donor transplants and the use of 
mobilized peripheral blood as stem cell source27. Although Scl-models generally parallel 
with a severe form of clinical cGVHD, one shortcoming of the Scl-cGHVD models is 
that they don't regenerate the autoimmune phenotypes seen in patients and B cells don't 
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seem to be required in the pathogenesis of the models. As a result, discoveries based 
solely on these models may not be readily translatable to human clinic.  
 
Panoskaltsis-Mortari et al have developed a murine model that incorporates clinical 
relevant conditioning regimen and develops a wide spectrum of symptoms seen in 
patients28,29.  In this model, B10.BR (H2k) recipients are conditioned with 
cyclophosphamide (120mg/kg body weight) and total body irradiation (830 Gy), 
followed by tail vein infusion of B6 donor T cell depleted bone marrow cells and ~70,000 
purified T cells (Figure 1). Transplanted mice lose about 20% body weight at 8-weeks 
post BMT and have ≥80% total survival rate. 
 
The phenotypic hallmark of this model is the development of multi-organ disease 
including lung, liver, tongue, spleen, thymus and colon. Fibrosis development in lung and 
liver can be detected as early as 4 weeks post-BMT and proceed to at least 12 weeks post-
BMT.  Importantly, fibrosis development in the lung results in BO, which is a late-stage 
complication of GVHD and happens to 6% of GVHD patients. The 5-year survival rate 
of BO is estimated by the National Institutes of Health to be only 10%.  BO can be 
detected by in vivo lung function measurements using the FlexiVent measurement. This 
technique allows for the in vivo functional monitoring the development of disease and 
therapeutic effect of treatments, which is not available for other models.  
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The loss of pulmonary function and development of BO is mediated by donor T cells and 
B cells infiltration, antibody deposition, and macrophage infiltration in the peri-
bronchiolar and peri-vascular area. Histologically, lungs of disease mice display 
peribronchiolar and perivascular cuffing and infiltration of the airway epithelium. The 
pathology appeared predominantly bronchiolar, with some alveolar involvement. 
Completely occluded bronchioles are observed in 20% of the animals in this model. The 
pattern of inflammation along with increased collagen deposition surrounding non-
obliterated bronchioles was similar to the pathology that defines occluded bronchioles in 
humans28. In addition, TGF-β staining in these areas is also increased. TGF-β is a central 
player in fibrotic responses. Macrophages may be the main producer of TGF- β and the 
immunohistological staining of both co-localized with each other. Spontaneous germinal 
center reaction is the immunological hallmark of this model. Increased germinal center B 
cells frequency in spleen, enlarged germinal center and increased follicular help T cells 
and regulatory T cell ratio can been seen after 6 weeks post BMT.  
 
This model incorporates clinical relevant pre-conditioning regimen including both 
cyclophosphamide and irradiation, which are commonly used in treatment protocols of 
blood malignancies. In addition, irradiation is commonly performed before BMT in 
human to enhance immune suppression and make niche for the coming donor bone 
marrow. In the Bo model, Cyclophosphamide exacerbates TBI-induced glutathione 
redox reactions in the recipients tissues, along with sublethal doses of donor T cells (to 
avoid aGVHD) favored the generation of cGVHD30. Thus, the BO model closely mimic 
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the pre-conditioning regimen used in human BMT. Another advantage of the BO model is 
that the mechanism of this model linked autoimmune and pro-fibrotic pathways, both of 
which are seen in human cGVHD. Using the BO model, mechanisms leading to cGVHD 
have been elucidated and potential drug targets and treatment methods have been 
identified. This includes methods that inhibit germinal center reactions such as 
lymphotoxin-β receptor (Lymphotoxin Beta Receptor) - immunoglobulin fusion protein, 
Tregs infusion and iNKTs infusion. Strategies that block B cell and T cell signaling 
pathways such as Ibrutinib drug targeting Bruton’s tyrosine kinase (BTK) and IL-2 
inducible T cell kinase (ITK) and GNF362 drug targeting Inositol-trisphosphate 3-kinase 
B (Itpkb) are effective in reversing cGVHD in the BO model. Pirfenidone that target the 
pro-fibrotic pathways show efficacy in the BO model. IL-21 is required for T follicular 
helper cells and germinal center B cells interactions and IL-17 is important for cGVHD 
pathogenesis, thus targeting Rho-associated kinase 2 (ROCK2), a regulator of IL-17 and 
IL-21 decreases cGVHD.  
 
However, there are several points to take into consideration when translating experiment 
results from this model to human clinic. For example, the donor and recipient mouse 
strain in this model are MHC mismatched, while in human BMT, the majority cases are 
MHC matched and miHAs mismatched. The level of genetic disparities affects not only 
the disease severity, but also the mechanism as to how disease develops, since MHC 
molecule is crucial for antigen presentation. In addition, the targets of antibodies 
developed in this model are to be studied. 
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1.3 Pathogenesis of cGVHD 
1.3.1 T cells  
T cells play a continuous role in cGVHD pathogenesis. In the initiation stage, factors 
such as pre-transplant conditioning and previous aGVHD cause tissue damages and the 
subsequent release of pathogen associated molecular patterns (PAMPs) and damage 
associated molecular patterns (DAMPs). These molecules activate APCs such as 
macrophages, dendritic cells, and B cells. Activation of these cells results in the 
production of pro-inflammatory molecules that not only aggravate tissue injury, but also 
activate and shape donor T cells contained in the grafts as well as donor bone marrow 
derived T cells into different linages31. Various approaches that deplete donor T cells 
from grafts reduce the subsequent incidence and severity of chronic GVHD. These 
include positive selection of CD34 stem cells as well as methods to deplete T cells, such 
as targeting pan–T-cell antigens. T-cell depletion in vivo with antithymocyte globulin 
(ATG) administered in the peritransplant period reduces the incidence of cGVHD without 
affecting graft versus leukemia effect32,33. Early post-transplantation course of high-dose 
cyclophosphamide has been shown to reduce the incidence and severity of cGVHD34.  
 
Strategies that alter T cell trafficking, TCR or cytokine receptor signalings have also been 
explored33. Ibrutinib inhibits interleukin-2 (IL-2)–inducible kinase (ITK), which is highly 
expressed in T cells. In murine models, inhibition of both Bruton’s tyrosine kinase (BTK)  
and ITK by ibrutinib contributed to the prevention of chronic GVHD35. Ruxolitinib, a 
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selective inhibitor of Janus kinase 1 (JAK1) and JAK2 mediate receptor-mediated 
signaling for a variety of proinflammatory cytokines, including interferon-γ and IL-6, and 
inhibition of this pathway has been shown to suppress activation and differentiation of 
dendritic cells as well as T cells. Inhibition of JAK1/JAK2 signaling with ruxolitinib has 
been shown to reduce cGVHD in murine models and human patients36. Targeting 
ROCK2 decreases cGVHD. ROCK2 is an enzyme that regulate IL-17 and IL21 by 
KD025 decreases cGVHD in multiple murine models37.  
 
During active cGVHD, T cell homeostasis is disturbed and the balance between different 
linages is disrupted. While aGVHD is considered as a Th1 dominant disease, the scenario 
of cGVHD is much more complicated.  Th17 has been implicated in cGVHD 
pathogenesis38. In systemic sclerosis, a condition closely resembling scleroderma, the 
predominant clinical feature of cGVHD after aHSCT, fibrosis is mediated by Th17 cells 
infiltrating the skin and serum IL-17 levels positively correlate with disease severity39. 
Malard reported increased Th17 cells and Th17/Treg ratio in the liver biopsy of cGVHD 
patients40. An activated Th17 prone T cell subset (CD146+) is increased in a cohort of 20 
aGVHD patients. In addition, CD146-/- donor T cells fail to induced cGVHD in the BO 
model41.   
 
1.3.2 B cells and antibodies 
Several early observations on cGVHD patients pointed out that cGVHD may have 
autoimmune features: 1. several different types of auto-antibodies were identified from a 
		 14	
cohort of 40 cGVHD patients, including antibodies against both surface and intracellular 
antigens42; 2. IgM and complement were detected in the dermo-epidermal areas of 
cGHVD skin, but not or less in the healthy controls43; 3.Besides antibodies that target 
self-antigen, antibodies against allo-antigen have also been identified. Male HCT patients 
with female donors develop high titer H-Y antigen specific antibody responses 4-12 
months after sex-mismatched transplantation in association with chronic GVHD44. The 
existence of circulating auto/allo-antibodies suggested a pathogenic role for B cells in 
cGHVD. Thus B cell targeting therapies have been extensively explored in cGHVD45. 
For example, anti-CD20 monoclonal antibody shows clinical and histological efficacies 
in 5 patients with refractory cGHVD46. Multiple phase II trials using rituximab therapy 
(anti-CD20 monoclonal antibody) have confirmed an important B cell role in chronic 
GVHD with overall rituximab response rates ranging 40-70% rate in steroid refractory 
cGVHD patients47–49.   
 
Although autoantibodies have been frequently associated with cGVHD, there have been 
discussions regarding the clinical significance of the autoantibodies.  A cohort of 280 
cGVHD patients were examined the presence of a broad array of autoantibodies in serum. 
Analysis shows that no significant associations were found between cGVHD activity and 
severity, and presence of autoantibodies50, while another study of much smaller cohort 
suggested association between autoantibody and cGVHD51. To understand the role of 
antibody, Srinivasan et al transplanted mice with bone marrow from (m+s) IgMxJhD 
BALB/c donors. These mice are capable of generating membrane-bound IgM and 
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secreting IgM, but they produce and secrete >100-fold less antigen- specific IgG than 
similarly immunized wildtype (WT) controls. Recipients of bone marrow from these 
mice have significantly better pulmonary function, compared with recipients of WT bone 
marrow29. This experiment clearly showed that B cell's role in cGVHD is antibody 
dependent. In addition to this, Defu Zeng et al used an (Ig)Hmg1 DBA/2 mice whose B 
cells have normal APC and regulatory function, but cannot secrete antibodies, to prove 
antibody production is required for cGVHD development in the scleroderma model52. 
Adoptive transfer of cGVHD antibody to healthy mice resulted in cGVHD target tissue 
deposition of these antibodies29, further supporting that antibodies play an active role in 
cGVHD pathogenesis. However, how these antibodies mediate cGVHD remain a 
question to be answered.  
 
The differentiation of mature B cells is a dynamic and highly regulated process  
(illustrated in Figure 2) that includes both deletion of autoreactive B cells and positive 
selection of B-cell clones capable of recognizing a broad repertoire of foreign antigens. In 
the bone marrow, the first tolerance check point happens at the "immature B cell" stage 
where B cells start express functional B cell receptor IgM on the surface that can bind to 
antigens. If the IgM shows reactivity to self-antigen, B cells expressing that IgM will be 
removed from the repertoire by mechanisms such as clonal deletion, receptor editing and 
apoptosis53. In healthy individuals, B-cell development begins with the continuous 
production of precursor B cells in the bone marrow that are exported to the periphery as a 
large pool of transitional B cells. More than half of the developing B cells in the bone 
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marrow express autoreactive B-cell receptors (BCRs). These autoreactive B cells are 
usually deleted or anergized but failure of tolerance checkpoints can lead to escape from 
deletion of self-reactive B cells and the production of autoantibodies and autoimmune 
disease54. Auto-reactive B cells are highly B cell activating factor (BAFF) dependent.  
The low BAFF concentrations in B cell microenvironment are not enough to support 
autoimmune B cells survival in healthy individuals. However, in the setting of aHSCT 
and cGVHD, BAFF concentrations are significantly increased55,56, while high levels of 
BAFF promote the differentiation and survival of auto-reactive B cells. In addition to 
increased BAFF level, the BM output of transitional and mature naive B cells are reduced 
during cGVHD as a result of pre-BMT conditioning, preventative immune suppression 
and occurrence of acute GVHD. Thus B cell reconstitution is generally slow. In contrast, 
patients who have normal numbers of naive and circulating transitional B cells after 
aHSCT are common in patients who do not go on to develop cGVHD. These 
observations suggest that increased BAFF/B cell ratio contributes to abnormal B-cell 
homeostasis characteristic of cGVHD. Thus treatments targeting B cell signaling and 
promoting bone marrow function recovery after BMT warrant further exploring.  
 
In addition to elevated BAFF/B cell ratio, there is increasing evidence suggesting 
aberrant B cell signaling during cGVHD. B cells in cGVHD patients showed evidence of 
increased metabolic activity and survival, with enhanced signaling via the AKT and ERK 
pathways57. Signaling after BCR engagement by antigen entails phosphorylation and 
activation of the tyrosine kinase SYK (spleen tyrosine kinase), which subsequently 
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phosphorylates and activates the tyrosine-rich adapter protein B cell linker protein 
(BLNK) that is then recruited to the BCR signalosome. BLNK is central to downstream 
signaling, as it also acts as a docking protein for BTK, and other crucial BCR complex 
signaling molecules. Using anti-IgM as a surrogate for soluble antigen, Allen et al found 
that cGVHD B cells not only responded more robustly after exposure, but that this 
response was associated with increased protein levels of the proximal BCR machinery 
molecules SYK and BLNK58. The SYK inhibitor fostamatinib abrogated BCR activation 
and limit proliferative and survival advantage of human cGVHD B cells58.  This finding 
was extended by Flynn et al, showing that SYK phophorylation is increased during 
murine cGVHD and is necessary in donor-BM-derived cells for the development and 
maintenance of cGHVD in the BO model. In addition, therapeutic pharmacologic 
inhibition of SYK decreases pathology in a murine BO model of cGVHD59. BTK is 
highly conserved Tec family kinase that propagates immune receptor-based signaling in 
B cells and is dispensable for antibody production. Blocking BTK by ibrutinib 
ameliorates cGVHD in both the scleroderma model and the BO model. These data 
suggest that BCR signaling after antigen engagement during post aHSCT B cell 
reconstitution is critical for persistence of auto-reactive B cells, and selective inhibition 
of BCR signaling may provide a new therapeutic target in patients with cGVHD. Indeed, 
ibrutinib was recently FDA approved as the only drug ever approved for treatment of 
steroid refractory GVHD.  
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In addition to a pathogenic role, B cells have beneficial role in cGVHD. Decrease of the 
frequency of a subset of IL-10 expressing B cells (Breg or B10 cells) has been correlated 
with human cGVHD60,61. The regulatory function of Breg cells has been demonstrated in 
mouse models of inflammation, cancer, transplantation, and particularly in 
autoimmunity62,63.  
 
1.3.3 Germinal center (GC) reactions 
GCs are specialized regions found in secondary lymphoid organs in which activated B 
cells undergo diversification and affinity maturation that result in differentiation into both 
memory B cells and long-lived plasma cells that produce high-affinity, antigen-specific, 
class-switched antibodies. GCs are required for a sustained humoral immune reaction to 
allo-reactive antigens but also could result in the production of auto-reactive antibodies 
and a dysregulated autoimmune response64. In the BO model, enlarged GC and increased 
GC density were observed and disruption of GC reaction by lymphotoxin-β receptor 
immunoglobulin fusion protein could block disease. Flynn et al further demonstrated that 
follicular helper T cells (Tfh) and GC B cells frequencies are increased in cGVHD mice. 
In human, the levels of circulating Tfh cells are decreased in patients with active 
cGVHD, but these Tfh cells are activated and have increased functional ability to 
promote B-cell maturation and immunoglobulin secretion. This phenomenon is likely due 
to increased homing of Tfh in to second lymphoid organs, suggested by increased serum 
CXCL1365.  Tfh migration to GC area by CXCR5 expression and the secretion of IL-21 
is necessary for cGVHD development. Disruption of Tfh and GC B interaction by anti-
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ICOS and anti-CD40 antibodies blocks cGHVD66. Patients with cGVHD frequently 
develop IgG antibodies directed at minor histocompatibility antigens in the recipient. In 
individual patients, these specific B-cell responses have been associated with clonal T-
cell responses directed against different peptide epitopes contained within the same 
antigen67,68. These observations suggest that coordinated T- and B-cell responses in GC 
reactions are associated with cGVHD pathogenesis and identified several potential 
treatment targets for cGVHD. 
The increased GC reactions may result from disturbed balance between Tfh and 
regulatory cells (Tfr). Tfr cells are effector subset of Tregs that originate from natural 
Treg precursors and express CXCR5, PD-1, ICOS, Bcl6 and Foxp3. The expression of 
CXCR5 directs them to migrate to GCs and suppress B cell responses69. McDonald-
Hyman et al reported a decreased Tfr frequency in cGVHD mice. Treg infusion after 
disease establishment reverses cGVHD in CXCR5 dependent manner70.  In vivo Treg 
expansion by iNKT infusion reversed cGVHD in the BO model71. These data suggested 
strategies restoring the balance between Tfh and Tfr in GC are promising for cGVHD 
treatment.  
 
1.3.4 Macrophages, TGF-β and fibrosis 
CD163+ macrophage infiltration of skin lesions after aHSCT was shown to be a 
significant predictive factor for refractory GVHD, as well as being a negative prognostic 
factor for overall survival72. The cumulative incidence of de novo–onset cGVHD was 
higher in patients with higher plasma soluble CD163 concentrations at day 80 than those 
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with lower concentrations. The use of granulocyte colony- stimulating factor (G-CSF)–
mobilized stem cell grafts clinically has been associated with increased cGVHD73. This is 
likely due to the amplification effect of G-CSF on IL-17A production, which controls the 
infiltration of macrophages into skin and cutaneous fibrosis74. In a sclerodermatous 
cGVHD model, donor M2 macrophages infiltrating the skin were noticed and G-CSF 
treatment after transplantation exacerbated macrophage infiltration and cutaneous 
pathology. In addition, depletion of macrophages using an anti–CSF-1R mAb markedly 
reduced cutaneous and pulmonary cGVHD26.  Increased CD68+ macrophages are 
associated with liver fibrosis in a humanized cGVHD mouse model75. These study 
collectively suggested that macrophage plays an active pathogenic role in cGVHD 
pathogenesis. However, how macrophages contribute to cGVHD pathogenesis is largely 
unknown. We recently reported co-localization of macrophage marker F4/80 and TGF-β 
in the peri-bronchiolar areas of cGVHD lungs in the BO model, the same area where 
extensive collagen deposition occurs. In addition, the percentage of latency associated 
peptide (LAP, correlate with TGF-β production) expressing lung macrophages as well as 
the expression level of LAP are increased during cGVHD24. Levels of TGF-β mRNA 
were found to be highest in skin biopsies of cGVHD patients when compared to patients 
with aGVHD76. T cells and macrophages in the cGVHD skin express TGF-β1 but not 
TGF-β2 or TGF-β3 mRNA25. In addition, macrophages express very high levels of Fc-γ 
receptors and are highly efficient at opsonization of antibody-coated targets, which in 
turn can generate very high levels of TGF-β. These data suggested that the interaction of 
allo-(and/or auto) antibody with tissue macrophages and production of TGF-β might be 
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the mechanism driving tissue fibrosis during cGVHD. 
TGF-β ligands signal through cell surface serine/threonine kinase receptors, known as 
type I and type II receptors. Following ligand binding and receptor phosphorylation, the 
SMAD signaling circuitry becomes activated. The SMAD proteins are a family of 
transcription factors consisting of 8 members, SMAD1-8, which are further subdivided 
into 3 classes based on structural and functional properties. Receptor-regulated SMADs 
(R-SMADs), SMAD1, 2, 3, 5, and 8, are the only SMADs directly phosphorylated and 
activated by the kinase domain of type I receptors. Upon phosphorylation, R-SMAD form 
a complex with the common SMAD, SMAD4, resulting in nuclear accumulation of 
activated complexes. In the nucleus, R-SMAD–SMAD4 complexes cooperate with 
transcriptional coregulators that further define target gene recognition and transcriptional 
regulation. The inhibitory SMADs, SMAD6 and SMAD7 function to inhibit TGF-β 
signaling77,78. TGF-β has been recognized as a central player of fibrotic responses 
because of its abilities including by not limited to (1) promote epithelial and endothelial 
cells to acquiring mesenchymal phenotypes, (2) recruitment of circulating fibrocytes and 
bone marrow–derived progenitor cells to the lung, and (3) activation, migration, and 
proliferation of resident fibroblasts and their differentiation into activated myofibroblasts, 
which promotes excessive extracellular matrix (ECM) deposition and abnormal collagen 
accumulation79,80. Due to the regulative role of TGF-β on multiple immune cells, 
targeting TGF-β has been explored in many diseases including cancer and fibrosis81. 
Targeting TGF-β in cGVHD has been published by several groups. Administration of a 
neutralizing antibody against TGF-β prevented or reduced virtually all cutaneous 
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manifestations of chronic GVHD, including cellular infiltration, immune cell activation, 
thickening and fibrosis23. Early neutralization of TGF-β after BMT led to increased 
aGVHD, while late neutralization of TGF-β (days 14–42 post-transplant) led to decreased 
cGVHD scores and reduced pathophysiology in both the GI tract and the skin82. 
Additionally, blocking SMAD3 phosphorylation has been proposed as one way to 
alleviate cGVHD symptoms83. Results from multiple murine models suggested TGF-β 
can be a target for cGVHD treatment. Gene array analyses have shown that decreased 
expression of components of the TGF-β signaling pathway in donor CD4+ and CD8+ 
cells is correlated with increased incidence of cGVHD in recipients84. In a murine 
cGVHD model, recipient Tregs that survived irradiation suppress development of 
cGVHD85, possibly through the production of TGF-β86. These study suggested that the 
role of TGF-β in cGVHD is time sensitive and context dependent. Localized inhibition of 
TGF-β to reduce fibrosis and minimize effect on Treg warrants further exploration.  
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Figure 1.  
 
Figure 1. Schema of a BO model 
B10.BR are conditioned by 2 doses of Cy (days -3 & -2) and total body irradiation (day-
1). On day 0, conditioned B10.BR mice receive 107 B6 T-cell depleted BM without or 
with ~70,000 purified B6 T cells. Mice received BM with T cells will develop cGVHD 
with BO that can be detected on day 28. GC enlargement and collagen deposition in the 
lung can be detected around day 56. To evaluated therapeutic effect of a drug, mice are 
usually treated from day 28 to day 56 post transplantation.   
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Figure 2. 
 
Figure 2. Development and differentiation of B cells 
B cells originate from HSCs that have self renewal ability and the potential to generate all 
blood cells. HSCs differentiate into multi-potent progenitors (MPPs) and common 
lymphoid progenitors (CLPs) by interacting with bone marrow stromal cells. Signals that 
are important for early B cells development are FLT3L, SCF and CXCL12. BCR heavy 
chain rearrange starts at CLP and continue through Pro B cell stages. Expression of 
certain transcription factors combination such E2A, EBF and PAX5 by Pro B cell secures 
the progenitor cell a B cell fate. If a Pro B cell express a successful heavy chain, then the 
rearrangement stop and start to proliferate. The rearranged heavy chain can pair with a 
surrogate light chain and form a pre-BCR, which mark the B cell a pre-B cell. Pre B cell 
proceed to rearrange light chain. Once successfully assembling a light chain gene, the cell 
becomes an immature B cell that expresses a complete IgM and later an additional IgD 
on the cell surface. This stage of B cell is called transitional B cells, which migrate from 
the BM, through the blood into second lymphoid organs (SLO), where the transitional B 
cell meets its cognate antigen and become a mature B cell. Antigen binding mature B 
cells migrate to the B cell follicle in second lymphoid organ. At the border of B cell 
follicle and T cell zone, cognate T cell provides help to follicle B to undergo proliferation 
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and further differentiation. There are 3 fates for the follicle B cells. They can differential 
to memory B cell or short live plasma cell. The majority B cells will migrate to germinal 
center, where with the help of Tfh, they undergo somatic hyper mutation, class switch 
recombination and clonal expansion. Germinal center B cells will further differentiate 
into memory cell and long-lived plasma cell that secrete high affinity antibodies.  
There are two check point to prevent B cell auto reactivity. The first one is in the BM, 
where BCR is tested for autoreactivity. Autoreactive B cell will be removed from the 
reptovire by mechanism such as receptor edition, apoptosis and anergy. Another check 
point in SLO has been proposed but the mechanism is largely unknown.  
In cGVHD, the sites of both central and peripheral tolerance are target of disease, thus 
may compromise tolerance mechanism. The compromised tolerance mechanism together 
with an autoimmune prone milieu, facilitate B cell autoimmunity in cGHVD.  
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Chapter 2 Inositol kinase Itpkb is a novel therapeutic target for chronic graft versus 
host disease (cGVHD) 
		 27	
Abstract 
Chronic graft versus host disease (cGVHD) is a common and life-threatening 
complication of allogeneic hematopoietic stem cell transplantation. cGVHD is mediated 
by donor T cells recognizing and attacking host tissues followed by activation of effector 
cells such as B cells to product pathogenic autoantibodies and macrophages to mediate 
fibrotic responses.  Safer and more effective therapies are needed for cGVHD treatment. 
Inositol 1,4,5-trisphosphate 3-kinase B (Itpkb) is a Ca2+
 
dependent kinase downstream of 
lymphocyte receptor signaling that regulates T and B cell homeostasis and function by 
controlling the intracellular Ca2+
 
level, thus regulating apoptotic responses. Genetic 
deletion of Itpkb results in apoptosis. GNF362, a low molecular weight Itpkb inhibitor 
blocks T cell driven autoimmunity. In this study, we explore the role of Itpkb in cGVHD 
pathogenesis and hypothesize that cGVHD can be prevented by disrupting the Itpkb 
signaling pathway. We test the hypothesis in two preclinical cGVHD models with distinct 
clinical manifestations and pathophysiology, including a multi-organ system cGVHD 
mouse model that is characterized by bronchiolitis obliterans (BO) driven by spontaneous 
germinal center reactions and antibody deposition, and a scleroderma model that is 
characterized by macrophage infiltration and skin fibrosis. This study demonstrates that 
depleting Itpkb in donor T cells, but not in donor bone marrow blocked cGVHD lung 
disease and germinal center reaction in the BO model. In addition, pharmaceutical 
inhibition of Itpkb with GNF362 significantly reduced cGVHD manifestations in both 
models. These data identify Itpkb as an essential mediator of cGVHD pathogenesis and 
suggest Itpkb inhibition as a novel approach to treat cGVHD.   
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Introduction  
cGVHD is the major obstacle for allogeneic hematopoietic stem cell transplantation 
(aHSCT) patients. Mortality caused by cGVHD is only second to relapse in long-term 
survivors of aHSCT. Although significance advance has been made in understanding the 
mechanisms of cGVHD pathogenesis, there has been limited change in the standard 
therapies of cGVHD, which rely mainly on systemic immune suppressions87. However, a 
significant portion of cGVHD patients do not respond to current standard therapies and 
the ones who respond are at higher risk of malignancy relapse and infection.  
 
cGVHD is initiated by donor T cells activation and sustained by T and B cells interaction 
in germinal centers to produce high affinity self reactive autoantibodies66–68. Targeting T 
and B cell signaling has been explored in cGVHD treatment49. T and B cell receptor 
signaling pathways are tightly regulated by a number of mechanisms to ensure proper 
maturation, activation and function. Calcium (Ca2+) signals in lymphocytes participate in 
the regulation of cell differentiation, gene transcription and effector functions88. An 
increase in intracellular levels of Ca2+ results from the engagement of immunoreceptors, 
such as the T-cell receptor, B-cell receptor and Fc receptors, as well as chemokine and 
co-stimulatory receptors88. In lymphocytes, receptor engagement activate phospholipase 
C-γ (PLC-γ), which hydrolyzes phosphatidylinositol-4,5-bisphosphate (PIP2) into 
diacylglycerol and inositol-1,4,5-trisphosphate (IP3), an essential second messenger 
mediating Ca2+ release from the endoplasmic reticulum. IP3-mediated depletion of 
endoplasmic reticulum Ca2+ stores triggers the opening of store-operated Ca2+ (SOC) 
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channels in the plasma membrane, leading to sustained increases in intracellular Ca2+, 
which are required for cell cycle entry and gene expression89. The calcium-dependent 
inositol kinase, Itpkb phosphorylates the 3’ position of the inositol ring to convert IP3 to 
inositol 1,3,4,5-tetrakisphosphate (IP4), thus act as an negative regulator of intracellular 
Ca2+ level90. Itpkb is implicated in autoimmune responses. During B cell development 
and maturation, Itpkb negatively regulate BCR signaling strength and control B cell 
selection and tolerance induction91. Mice lacking Itpkb had impaired B lymphocyte 
development and defective IgG3 antibody responses to a T lymphocyte–independent 
antigen92. Inhibition of Itpkb in mature T lymphocytes results in enhanced intracellular 
calcium levels following antigen receptor activation leading to T cell death. Deletion of 
Itpkb or treatment with Itpkb inhibitors blocks T-cell dependent antibody responses in 
vivo and prevents T cell driven arthritis in rats92. In this report, we study the role of Itpkb 
in the development of cGVHD in 2 complementary pre-clinical murine models including 
the germinal center response driven systemic model with BO and the scleroderma model.  
 
Materials and methods 
Mice  
C57Bl/6 (B6; H2b), Balb/c (H2d) and B10.D2 (H2d) mice were purchased from the 
National Cancer Institute and used at 8-12 weeks old. B10.BR (H2k) mice were 
purchased from the Jackson Laboratory and used at 10-14 weeks old. Itpkbfl/+ mice in B6 
background were generated in the Genomic institute of the Novartis Research 
Foundation93 and transferred to University of Minnesota. Itpkbfl/fl offspring from the 
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Itpkbfl/+ parents were crossed with B6 mice that express CRE under the control of the 
triple mutant form of the human estrogen receptor; which does not bind its natural ligand 
(17β-estradiol) at physiological concentrations but will bind the synthetic estrogen 
receptor ligands 4-hydroxytamoxifen (OHT).	Tamoxifen injections delete the Itpkb gene. 
Animal protocols were approved by Institutional Animal Care and Use Committee at the 
University of Minnesota.  
 
Induction of cGVHD in vivo  
For the BO cGVHD model, B10.BR mice were conditioned with intraperitoneal Cytoxan 
(Sigma, 120mg/kg/day, i.p., day-3&-2) and total body irradiation (8.3 Gray delivered by 
x-ray [list machine, dose rate) on day-1), followed by infusion of 107 B6 T cell depleted 
bone marrow (TCD-BM) only as non-cGVHD control, or plus 70,000 purified splenic T 
cells to induce cGVHD (day 0)24. For the scleroderma model, BALB/c mice were 
conditioned with TBI (7.75 Gray, day0), followed by infusion of 10×106 B10.D2 TCD-
BM only or plus 1.8×106 CD4 and 0.9×106 CD8 T cells (day0) 22. 
 
GNF362 Treatment 
GNF362 was identified via high-throughput compound screening and optimized for drug-
like properties using medicinal chemistry in Genomics Institute of the Novartis Research 
Foundation (GNF)93. GNF362 was formulated at 2mg/mL in 20% hydroxyl propyl-beta 
cyclodextrin in water. Mice were then dosed orally with GNF362 at 200 microgram dose 
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or vehicle twice daily from day 28-56 for the BO model and day 21-55 for the 
scleroderma model.  
 
Pulmonary function tests: Pulmonary function tests were performed as described 
previously28. Briefly, Nembutal anesthetized mice were intubated and ventilated using the 
Flexivent system (Scireq). Pulmonary resistance, elastance and compliance were 
recorded and analyzed using the Flexivent software version 5.1.  
 
Histopathology and immunostaining:  
Lung, liver and skin were embedded in Optimal Cutting Temperature (OCT) compound, 
snap frozen in liquid nitrogen, and stored in -80°C. Lungs were inflated by 75% OCT 
prior to harvest. For trichrome staining 8 µm cryosections were fixed for overnight in 
Bouin’s solution and stained with the Masson’s trichrome staining kit (Sigma HT15). 
Collagen deposition was quantified as a ratio of blue area to total area by ImageJ.  
 
For immunostaining, acetone fixed 8µm cryosections were stained with indicated 
markers. For macrophages staining, frozen sections of lung or skin were stained with anti 
CD68-ef660 (FA-11, eBioscience 50-0681).  For immunoglobulin deposition, sections of 
lung were stained with goat anti-mouse Ig (BD 55401). Confocal images were acquired 
on an Olympus FluoView500 Confocal Laser Scanning Microscope 
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Flow Cytometry: For Tfh and GC B cells, single cell suspension of spleens was obtained 
and stained with fixable viability dye, fluorchrome-labeled anti-CD4 (RM4-5, BD), anti-
CXCR5 (SPRCL5, eBioscience), anti-PD-1 (J43, eBioscience), anti-CD19 (eBio1D3, 
eBioscience), anti-GL7 (GL-7, eBioscience) and anti-Fas (J02, BD). GC B cells were 
defined as Fas and GL7 double positive CD19 B cells. Tfh cells were defined as PD1 and 
CXCR5 high CD4 T cells.  Cells were analyzed on BD LSRFortessa. 
 
Statistical analysis: GraphPad Prism 6 was used to conduct the statistical analysis. 
Groupwise comparisons were made by unpaired student T-test. Error bars indicated 
means +/- standard error of the mean (SEM). Significance: *P<0.05; **P<0.01; ***P< 
0.001; ****P<0.0001. 
 
Results and discussion: 
Itpkb in donor T cells is required to cause cGVHD in the BO model 
Itpkb functions downstream of TCR and BCR signaling pathways and negatively regulate 
intracellular Ca2+ level, thus regulates lymphocytes development, differentiation and 
function88. Itpkb inhibition blocked T cell dependent antibody production in a rat arthritis 
model93. Thus we determined to test whether Itpkb depletion or blockade can affect the 
antibody driven fibrosis in the BO model.  Since the cGVHD is initiated by donor T cell 
allo-responses and sustained by donor BM derived B cells and macrophages, we 
transplanted mice with Itpkb-/- or WT BM alone or with Itpkb-/- or WT T cells. To deplete 
the Itpkb gene, Itpkbfl/fl-CRE mice were treated with Tamoxifen for 5 days and rested for 
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a week before BM and T cells harvesting. Pulmonary function tests indicated that 
recipients of WT BM and Itpkb-/- T cells did not develop lung fibrosis - the phenotypic 
hallmark of the BO model, suggesting itpkb is required in donor T cells to cause cGVHD. 
This result correlate with previous report showing Itpkb is required for T cell activation 
and function, and loss of it triggers T cells apoptosis93. In contrast to the effects in donor 
T cells, Itpkb expression in BM is dispensable for cGVHD progression, as recipients of 
Itpkb-/- BM and WT T cells still developed lung disease as severe as mice received WT 
BM and WT T cells (Figure 1A). We further examined lung and liver by Masson’s 
trichrome staining and immunofluorescent staining to look at collagen and Ig deposition, 
which are apparent in cGVHD29.  Itpkb-/- donor T cells recipients did not show extensive 
collagen deposition in the peri-bronchiolar and peri-vascular areas in lung and liver, 
while there was no difference between the groups receiving WT or Itpkb-/- BM and WT T 
cells (Figure 1B&C). Ig deposition in lung was also absent when donor T cells lack Itpkb 
(Figure 1D). In contrast, Ig deposition was present in the mice receiving Itpkb-/- BM and 
WT T cells. These results suggest that Itpkb signaling is required in donor T cells to 
initiate cGVHD and point out a difference in the requirement of Itpkb by lymphocytes 
during different stages of cGVHD: donor T cells rely on Itpkb to become activated and 
proliferate to initiate cGVHD in the early stage of disease, while donor BM derived B 
cells and T cells can function without Itpkb to sustain cGVHD pathogenesis.  
 
cGVHD pathogenesis is dependent on spontaneous GC reactions and the production of 
auto/allo reactive antibodies; thus we examined the effect of loss of Itpkb signaling in 
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donor T cells on GC reactions. About a 2 fold increase of GC reaction magnitude was 
seen during cGVHD, demonstrated by increased splenic GC B cell frequency (Figure 
2B), Tfh (Figure 2C) cell frequency and Tfh/Tfr (Figure 2d) ratio. However these 
increases were absent in mice receiving Itpkb-/- donor T cells, suggesting a failure of 
inducing autoimmune response by Itpkb-/- donor T cells. This result correlates with the 
previous result showing lack of pulmonary disease in the Itpkb-/- donor T cells recipients.  
 
Therapeutic pharmacologic inhibition of Itpkb decreases cGVHD in 2 preclinical 
murine cGVHD models with distinct clinical manifestations.  
Having demonstrated the requirement for Itpkb in donor T cells to cause cGVHD, we 
next sought to determine whether drug treatment in mice with established cGVHD would 
be similarly efficacious as Itpkb deletion in donor T cells. GNF362 is a highly selective, 
orally potent low molecular weight (LMW) inhibitor that binds to the ATP-binding 
pocket of Itpkb93. GNF362 has been show to reduce T cell dependent arthritis in a rat 
model. To reverse established cGVHD in the BO model, mice were treated with oral 
GNF362 from day 28 until the end of experiment, as we previously determined that 
cGVHD is consistently present by day 28 as measured by pulmonary function tests. 
GNF362 treated mice had significantly improved pulmonary function compared to 
vehicle treated mice (Figure 3A). We further examined whether this was associated with 
effects on GC reactions. Surprisingly, even though pulmonary disease was alleviated by 
GNF362, the frequencies of cells participating GC reactions stayed mostly untouched 
(Figure 3B-E).  
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Previously we’ve shown that macrophage infiltration in the lung is involved in cGVHD 
pathogenesis24,26. To understand the therapeutic effect of GNF362 on cGVHD, we 
examined macrophage infiltration in the lung. Macrophages infiltrated the lung of 
cGVHD mice. GNF362 blocked macrophage infiltration in the treatment group (Figure 
3F). These results suggest that therapeutic administration of GNF362 reversed cGVHD 
through effect on macrophage infiltration. Itpkb loss on HSCs resulted in the expansion 
of granulocyte monocyte progenitor but did not alter the number of peripheral monocyte 
count94. In a competitive in vivo setting, Itpkb-/- versus WT BM derived macrophages 
showed significantly reduced ability to repopulate the periphery95.  However, no study 
has addressed the effect of Itpkb loss on macrophage migration and function in an 
inflammatory environment. Ca2+ signal act as second messenger in Fc receptor, 
chemokine receptor and toll like receptor in macrophage88. Our observation suggests that 
itpkb may regulate macrophage migration in an inflammatory environment.  
 
In order to determine whether the effect of Itpkb inhibition by GNF362 attenuates murine 
sclerodermatous cGVHD, we used a miHA mismatched murine model involving lethally 
irradiated recipients. In the model, Balb/c recipients were lethally irradiated and infused 
with purified T cells from B10.D2 recipients. Skin scleroderma accompanied with loss of 
activity is the major clinical manifestation of this model. GNF362 treatment from day 21-
55 significantly improved clinical score (Figure 4A) as well as skin score (Figure 4B&C). 
Previously we’ve shown that M2 macrophages infiltration is apparent in the skin of the 
sclerodermatous mice. Here, we show that GNF362 treatment significantly reduced 
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macrophage infiltration (Figure 4D, quantified in Figure 4E). We further looked at the 
effect of GNF362 on cytokine production of T cells and showed that GNF362 
significantly reduce IFN-γ production from T cells. These results suggested that 
GNF362’s therapeutic effect in the scleroderma model is associated with reduced 
macrophage infiltration and T cell IFN-γ production.  
 
Taken together, this study identified Itpkb as a key enzyme for donor T cells to initiate 
cGVHD. Therapeutic inhibition of Itpkb reversed lung disease in the BO model and 
ameliorated skin disease in the scleroderma model. These results highlight Itpkb as a 
potential therapeutic target for cGVHD therapy.  
 
Figure legends: 
Figure 1. Itpkb is required in donor T cells but not BM to cause cGVHD  
Conditioned B10.BR mice were transplanted with WT or Itpkb-/- BM with or without 
70,000 WT or Itpkb-/- donor T cells. (A) Pulmonary function was evaluated at around 8 
weeks post transplantation. (B-D) Lungs and livers were taken for trichrome staining and 
immune stainng. (B) Collagen deposition in the lung was assessed by trichrome staining 
that identifies collagen in blue. Percent of collagen deposition area was quantified by Fiji 
software. (C) Liver collagen deposition staining and quantification. (D) 
Immunofluorescence staining of Ig deposition in the lung. Results shown are 
representative from 2 independent experiments with similar results.  
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Figure 2. Itpkb expression in donor T cells is required for the development of 
spontaneous germinal center reaction 
Splenocytes were harvested at 6-8 weeks post transplantation and were stained with 
markers for GC B cells (A), Tfh (B) cells and Tfr (C) cells. Ratio of Tfh/Tfr was 
calculated in (D). GC B cells are CD19+Fas+GL7+ population. Tfh cells are CD4+Foxp3-
CXCR5+PD1hi population. Tfr cells are CD4+Foxp3+CXCR5+PD1hi population. Results 
shown are representative from 2 independent experiments with similar results. 
 
Figure 3. GNF362 reversed cGVHD lung disease associated with inhibition of 
macrophage infiltration but without altering germinal center reactions 
Transplanted mice were treated with GNF362 or vehicle from 4 to 8 weeks post 
transplantation. (A) Pulmonary function test was performed around week 8. (B-E) 
Germinal center responses were assessed by measure the frequencies of GC B cells (B), 
Tfh (C), Tfr (D) and Tfh/Tfr ratio (E). GC B cells are CD19+Fas+GL7+ population. Tfh 
cells are CD4+Foxp3-CXCR5+PD1hi population. Tfr cells are CD4+Foxp3+CXCR5+PD1hi 
population. (F) Macrophages in the lung were staining by CD68-FITC. Quantification 
was done by Fiji software by measuring the percentage of positive staining areas. Results 
shown are representative from 3 independent experiments with similar results. 
 
Figure 4. GNF362 reversed skin scleroderma caused by cGVHD 
Conditioned Balb/c mice were transplanted with B10.D2 BM only or with 2.7 x 106 
purified T cells (CD4:CD8=2:1). GNF362 treatment (200 microgram per oral, twice 
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daily) started at around day21. (A) Clinical manifestations of cGVHD were assessed by 
giving scores to weight loss, activity, posture and fur condition. Healthy mice receive 
score 0. (B) Skin scores was assessed by measuring the area of skin with fur loss or 
sclerodermatous lesion. Intact skin was given score 0. (C) Photograph of mice in BM 
only group, vehicle treated cGVHD group and GNF362 treated group. (D) Macrophage 
marker CD68 and M2 macrophage marker CD206 were used to staining the skin of 
transplanted mice. (E) Quantification of macrophage in skin by Fiji software. (F-G) 
Lymph nodes were harvested on day 55 post transplantation and lymphocytes were 
stimulated in vitro. IFN-γ production was evaluated by flow cytometry. Results shown 
are representative from 2 independent experiments with similar results.  
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Chapter 3 Invariant Natural Killer T cells Ameliorate Murine Chronic GVHD by 
Expanding Donor Regulatory T cells 
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Abstract    
Chronic graft-versus-host-disease (cGVHD) can cause multi-organ system disease 
typically with autoimmune-like features, resulting in high mortality and morbidity due to 
treatment limitations. Invariant natural killer T cells (iNKTs), a small population 
characterized by expression of a semi-invariant T-cell receptor, rapidly produce copious 
amounts of diverse cytokines upon activation that exert potent immune regulatory 
function. Here, we show that iNKTs are significantly reduced in a cGVHD murine model 
that recapitulates several aspects of autoimmunity and organ fibrosis observed in cGVHD 
patients. Low iNKT infused doses effectively prevented and, importantly, reversed 
established cGVHD, as did third-party iNKTs. iNKTs suppressed the autoimmune 
response by reducing the germinal center (GC) reaction, associated with an increase in 
total Tregs and follicular Tregs (Tfr) that control the GC reaction along with pathogenic 
antibody production. Treg depletion during iNKT infusions completely abolished iNKT 
efficacy in treating cGVHD. iNKT cell IL-4 production and GC migration were critical to 
cGVHD reversal. In vivo stimulation of iNKT cells by alpha-galactosyl-ceraminde was 
effective in both preventing and treating cGVHD. Together, this study demonstrates 
iNKT deficiency in cGVHD mice and highlights the key role of iNKTs in regulating 
cGVHD pathogenesis and as a potentially novel prophylactic and therapeutic option for 
cGVHD patients.  
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Introduction  
cGVHD is the major cause of non-relapse morbidity and mortality that lacks effective 
and safe therapies87. Preclinical models have elucidated autoimmunity as the key of 
cGVHD pathogenesis, where dysregulated GC and extra-follicular B-cell responses can 
lead to the production of autoantibodies that initiate fibrotic responses66.  While Tregs can 
treat established murine cGVHD70, clinical Treg production can be challenging and 
sustaining Treg persistence likely requires an IL-2 source that is suppressed by Tregs. 
Thus, we have explored an alternative immune regulatory population, iNKT cells, that are 
not exquisitely IL-2 sensitive and are highly effective in limited cell numbers in 
preventing acute GVHD (aGVHD)96–98. iNKT cells have immune regulation function99, 
conferred by the rapid production of immune regulatory cytokines such as IL-4 and IL-
10100,101 and promote Treg expansion perhaps through a myeloid cell intermediate97,102. 
iNKT deficiency has been linked to autoimmune diseases (e.g. type 1 diabetes, 
rheumatoid arthritis and lupus)103–105. Donor graft iNKTs content and their capacity to 
expand have been associated with GVHD risk106–108. Total lymphoid irradiation and anti-
thymocyte globulin conditioning in allo-HSCT patients results in an increase in the ratio 
of host iNKTs to conventional CD4+/CD8+ T cells which can reduce aGVHD in murine 
models and patients109,110. Here, we used a murine model of cGVHD induced by GC 
reaction that results in antibody production, deposition and triggering of 
monocytes/macrophages to cause systemic fibrosis, to evaluate the role of iNKT in 
preventing and treating cGVHD.  
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Materials and Methods 
Mice and bone marrow (BM) transplantation  
C57BL/6 (B6) (Charles River), B10.BR (JAX®), CXCR5-/- and IL4-/- on B6 background 
(JAX®) and B6.Foxp3.Luci.DTR-4 mice (gift from Professor Günter Hämmerling) were 
housed in a pathogen-free facility and used with IACUC approval.  To induce cGVHD, 
B10.BR mice were given cyclophosphamide and total body irradiation pre-transplant and 
B6 bone marrow (BM) only (no cGVHD) or with 75,000 purified T-cells (cGVHD)66. 
 
iNKT isolation and Treg depletion 
iNKT cells were FACS-sorted from CD1d-PBS57 tetramer enriched B6 splenocytes98 to 
high purity (>95%) and maintained cytokine-producing function (not shown). iNKTs 
were infused at 50,000 or 100,000 doses at the indicated times. Where stated, Tregs were 
depleted in B6.Foxp3.Luc-DTR-4 mice by diphtheria toxin (DT) (0.1 microgram/mouse) 
injections before and after iNKTs infuson (d.-2,-1,1& 2).  
 
cGVHD evaluation 
cGVHD was evaluated by pulmonary functional tests (PFTs) and trichrome staining29,66. 
Lung hydroxyproline quantification was per manufacturer’s instructions (Sigma 
MAK008). GC reaction was evaluated by immunofluorescence staining and 
flowcytometry66. Bioluminescent imaging (BLI) was performed using IVIS Spectrum.   
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Results and discussion 
Therapeutic iNKT cell infusion reversed established cGVHD 
To examine whether the iNKT pool in cGVHD is deficient, we analyzed splenic iNKTs 
from early phase cGVHD mice (d28) and naïve donor and host strain mice. cGVHD mice 
have a significantly lower splenic iNKTs than naïve mice and BM controls (Fig.1A-B). 
Thus, we explored adoptive iNKT transfer to treat cGVHD.  Donor iNKTs were infused 
to cGVHD on d28&42 post-transplantation. iNKTs (50,000 or 100,000 cells) reversed 
lung cGVHD measured by PFTs (Fig.1C). Total lung hydroxyproline (Fig.1D), collagen 
deposition around peribronchial and perivascular areas (Fig.1E&F) were reduced (50,000 
cells) or completely reversed (100,000 cells, this dose was used for subsequent studies). 
iNKT cells form a 3rd strain (Balb/c) reversed cGVHD as well as iNKT from donor strain 
(Fig.1G). iNKT infusion reduced GC area (Fig.1H&J) and increased Tfr density 
(Fig.1I&K). Flow cytometry analysis of d55 splenocytes confirms that iNKT reduces GC 
B and increases Tfr frequency (Fig.1L&M). Thus, donor iNKT reversal of established 
cGVHD was likely due to increased Tfr frequencies  
  
iNKT reversed cGVHD through donor Treg expansion 
Due to the reduced Treg frequency observed in both cGVHD patients111 and our murine 
model70, and reversal of cGVHD in murine model with Treg infusion70, we examined 
whether iNKT reversed cGVHD through Treg expansion. Donor B6.Foxp3.Luci.DTR-4 
mice112 permitted both tracking expansion and eliminating Foxp3 expressing Tregs, iNKT 
increased Foxp3 signal intensity by 2-fold (Fig.2A&B). Peri-infusion donor Treg 
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depletion completely abrogated iNKT-mediated protection as indicated by PFTs (Fig.2C), 
confirming a Treg dependent mechanism.  
 
Infused CD45.1 iNKT cells were detected in GC areas 5d after infusion (Fig.2D). To test 
whether GC migration and IL4 production are required for iNKT’s protective function in 
cGVHD, iNKTs from CXCR5-/- or IL4-/- mice were infused. Neither CXCR5-/- nor IL4-/- 
iNKTs were able to reverse cGVHD (Fig.2E). Taken together with the high Tfr frequency 
conferred by iNKT infusion, these data point to in-situ Tfr expansion in GC area by iNKT 
through IL4 dependent mechnism as a key mechanistic underpinning of iNKT-mediated 
cGVHD therapy. 
 
Pharmacologic activation of iNKT is effective in preventing and reversing cGVHD 
To determine the potential of iNKT in preventing cGVHD, donor iNKTs were given on 
d1&14 (prophylaxis) or on d28&42 (therapy). PFTs showed that prophylactic infusion 
completely blocked cGVHD, resulting in modestly more robust protection compared with 
therapeutic infusion (Fig.2F). Prophylactic iNKT efficacy may be advantageous due to 
the expansion of host radio-resistant Tregs or donor Tregs in the graft that suppress 
inflammation and tissue damage, preventing cGVHD initiation, as well as easier disease 
prevention than reversal. In support of this latter hypothesis and further demonstrating the 
potential iNKT therapeutic benefits, we demonstrated the efficacy of RGI2001, a 
liposomal formulation of a-galactosylceramide, in both treating and to an even greater 
extent in preventing cGVHD (Fig.2G).  
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Because aGVHD is a critical risk factor for cGVHD87, managing aGVHD can 
significantly reduce cGVHD incidence. iNKT infusion (25,000-100,000 cells) protected 
mice from aGVHD in a dose-dependent manner through Treg expansion97. These data 
and ours suggest that iNKT cells infusion protects from both aGVHD and cGVHD, 
which we speculate is due to the fact that both diseases are associated with an inadequate 
Treg pool and hence T effector/Treg ratio111,113. The fact that iNKT infusion is useful for 
both aGVHD and cGVHD offers the possibility for optimal treatment of patients with 
dual acute and chronic GVHD components114.  
  
Compared to Treg infusion, iNKT infusion required fewer cells (100,000 iNKT versus 
500,000 Treg in the same model) to reach optimal effect70,115. Additionally, iNKT cells 
have inherent anti-viral and anti-tumor abilities116 that are desirable for cGVHD patients. 
iNKT cells are persistent in host, as they can be detected in spleen, liver and lung at least 
2 weeks after infusion (not shown). A detailed migration/expansion profile of iNKT cells 
in cGVHD mice is to be studied. In summary, this study provides evidence that iNKT 
infusion and expansion are promising prophylactic and therapeutic options for cGVHD 
patients.  
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Figure Legends 
Figure 1. Therapeutic iNKT cell infusion reversed established cGVHD 
B10.BR mice were conditioned by 2 doses of cyclophosphamide (120mg/kg body 
weight, ip) on d-3 and d-2 of transplantation. On d-1, B10.BR mice were irradiated (830 
Gy by x-ray) then infused with T-cell depleted (TCD) BM only or with 75,000 purified T 
cells to induce cGVHD. (A-B) On d28 after transplantation, splenocytes were harvested 
from BM only mice and cGVHD mice and naïve mice of donor and recipient strains. 
Cells were stained with fluorochrome conjugated PBS57-CD1D tetramer, anti-CD4, anti-
TCR-β and viability dye. iNKT cells were identified by CD4+ TCR-β+PBS57-CD1D+ 
live cells. (A) Gating of iNKT cells. Cells were gated on live CD4+ T cells. (B) 
Frequency of iNKT is significantly reduced in cGVHD mice. (C-D) On d28 and d42 
post-transplantation, FACS sorted CD45.1 B6 iNKTs were infused to some cGVHD mice 
at a lower (50K) or higher (100K) dose. (C) Pulmonary function tests (PFTs) including 
resistance, elastance and compliance, were performed on d56 post transplantation. iNKT 
infusion significantly improves the pulmonary function. (D) Hydroxyproline was 
measured in the lungs of mice from Fig. 1C. iNKT infusion at the 100k cell dose 
significantly reduces hydroxyproline. (E) Trichrome staining that identifies collagen was 
performed on cryosections of lungs. (F) Collagen deposition was quantified by measuring 
the blue area of the Trichrome staining by Fiji software. iNTK infusion significantly 
reduce collagen deposition in the lung. (G) cGVHD was established previously 
described. Mice received Balb/c iNKT cells on d28 and 42. Balb/c iNKT cells reverse 
cGVHD. (H) Cryosections of spleen (d56) were stained with fluorochrome conjugated 
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anti-CD4 (FITC), anti-Foxp3 (eFluor660) and peanut-agglutinin (PNA) (CY3) and 
imaged by Olympus FV1000 system. Dotted lines delineate GC areas by PNA staining. 
(I) Follicular Tregs were identified as CD4+Foxp3+ cells within the GC areas. (J) Average 
GC size is decreased by iNKT. (K) Follicular Treg density is increased by iNKT. (L-M) 
Splenic GC B cells and follicular Tregs frequencies were determined by flow cytometry. 
iNKT infusion decreases GC B and increases follicular Treg frequencies. Unpaired 
student T-test was used when comparing 2 groups. Data shown are representative of 2 
independent experiments with 5-8 mice per group. Significance: *P<0.05; **P<0.01; 
***P< 0.001; ****P<0.0001. 
 
Figure 2. iNKT reversed cGVHD through donor Treg expansion and prevent the 
onset of cGVHD 
(A-C) cGVHD was established as per Fig 1, except that BM and T cells were harvested 
from B6.Foxp3.Luci.DTR-4 mice. Group 1 and 2 are BM only and cGVHD control as 
described before. Groups 3 - 5 are cGVHD mice that received diphtheria toxin (DT) 
(Group 3), iNKT infusion on d28 and d42 (Group 4) or iNKT infusion and DT (Group 5). 
(A) On d43, mice were imaged by Spectrum In Vivo Imaging system. (B) Quantification 
of the BLI signal shows depletion of Tregs by DT and expansion of Tregs by iNKT 
infusion. (C) PFTs were assessed as described in Fig 1. Treg depletion by DT injection 
completely abolishes iNKTs efficacy. (D) iNKT cells (white arrow) were identified by 
CD45.1+ in GC area. (E) Mice were transplanted as per Figure 1. iNKT cells from 
wildtype, CXCR5-/- or IL4-/- mice were infused to transplanted mice on d28 and 42. iNKT 
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cells from CXCR5-/- or IL4-/- mice lost the ability to reverse cGVHD. (F) cGVHD mice 
were infused with B6 iNKTs either on d1 and d14 (prophylaxis) or on d28 and d42 
(therapy). Prophylatic iNKT infusion completely blocks cGVHD. (G) Prophylatic or 
therapeutic RGI2001(2.5 microgram/mouse) was given to transplanted mice. PFTs 
suggest RGI2001 prevents and reverses cGVHD. 5-8 mice per group were analyzed for 
each assay. Significance: *P<0.05; **P<0.01; ***P< 0.001; ****P<0.0001.  
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Chapter 4  Pirfenidone Ameliorates Murine Chronic GVHD Through Inhibition of 
Macrophage Infiltration and TGF-β Production 
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Abstract  
Allogeneic hematopoietic stem cell transplantation is hampered by chronic graft-versus-
host disease (cGVHD) resulting in multi-organ fibrosis and diminished function. Fibrosis 
in lung and skin leads to progressive bronchiolitis obliterans (BO) and scleroderma, 
respectively, for which new treatments are needed. We evaluated pirfenidone, a FDA 
approved drug for idiopathic pulmonary fibrosis, for its therapeutic effect in cGVHD 
mouse models with distinct pathophysiology. In a full MHC-mismatched, multi-organ 
system model with BO, donor T cell responses that support pathogenic antibody 
production are required for cGVHD development. Pirfenidone treatment beginning one 
month post-transplant restored pulmonary function and reversed lung fibrosis, which was 
associated with reduced macrophage infiltration and TGF-β production. Pirfenidone 
dampened splenic germinal center B cell and T follicular helper cell frequencies that 
collaborate to produce antibody.  In both a minor histocompatibility antigen-mismatched 
as well as a MHC-haploidentical model of sclerodermatous cGVHD, pirfenidone 
significantly reduced macrophages in the skin, although clinical improvement of 
scleroderma was only seen in one model. In vitro chemotaxis assays demonstrated that 
pirfenidone impaired macrophage migration to MCP-1 as well as IL-17A, that has been 
linked to cGVHD generation. Taken together, our data suggest that pirfenidone is a 
potential therapeutic agent to ameliorate fibrosis in cGVHD.  
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Introduction 
cGVHD is a significant barrier of allogeneic hematopoietic stem cell transplantation 
(allo-HSCT) due to its high incidence and severity. Fibrosis affecting skin and internal 
organs is the predominant clinical feature of cGVHD. Bronchiolitis obliterans (BO) and 
scleroderma with their respective fibrotic bronchiolar and cutaneous changes87 are two of 
the most devastating outcomes for cGVHD patients. Systemic immune suppression is the 
recommended treatment for cGVHD, although such treatment is not always effective in 
controlling disease and does not alleviate established fibrosis117. Additionally, systemic 
immune suppression can be associated with high infection and relapse rates118. New 
therapies that reverse fibrosis without compromising immune function are urgently 
needed.  Several preclinical models have been developed to study cGVHD pathogenesis 
and test potential interventions21,119–121. For example, we have developed a murine model 
that uses full MHC-mismatched donors and recipients (B6→B10.BR) and incorporates a 
clinically relevant pre-transplantation conditioning regimen of high dose 
cyclophosphamide and total body irradiation (TBI) leading to the development of 
systemic fibrosis affecting the lung, liver and GI tract but not the skin. Studies from this 
model pointed to autoimmunity as the key of cGVHD pathogenesis, where induced 
germinal center (GC) reactions support the production of autoantibodies that are 
deposited in target organs causing fibrosis26,29,66. Two lethal irradiation models, 
(B10.D2→BALB/c22 and B6 parent→B6D2F26) using minor histocompatibility antigen-
mismatched or MHC-haploidentical donors and recipients, develop scleroderma as the 
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main cGVHD manifestation, which is dependent on tissue F4/80+ macrophage 
infiltration.  
 
Pirfenidone (5-methyl-1-phenyl-2- (1H)-pyridone) is a small molecule known for its anti-
fibrosis properties. In bleomycin-induced lung injury and lung allotranspant models, 
pirfenidone decreased hydroxyproline, fibrosis, procollagen I and II, PDGF isoforms, 
TGFb, fibroblast growth factor, and IL-13122–130.  Moreover, pirfenidone increases 
scavenger of reactive oxygen species131 and decreases inflammation pathways that 
initiate fibrosis responses, such as nitrites, IL-6132 and tumor necrosis factor-α133. 
Recently, pirfenidone has been FDA approved as treatment for idiopathic pulmonary 
fibrosis treatment, reducing disease progression and increasing lung function, exercise 
tolerance, and progression-free survival134. Pirfenidone showed efficacy in treating 
localized scleroderma in a phase II study135.  
 
In this study, we explored the efficacy of pirfenidone in multiple murine cGVHD models 
and found that pirfenidone reversed lung disease in the BO model. cGVHD patients with 
BO have a high morbidity and mortality and therapeutic options for advanced BO are 
limited136. We show that pirfenidone treatment of mice with active cGVHD was 
associated with a reduction of macrophage infiltration, TGF-β production, and the GC 
reaction. Importantly, pirfenidone administration had long-lasting effects and could 
reverse later stage lung disease. In the sclerodermatous cGVHD models, pirfenidone 
diminished macrophage infiltration in both models, although the clinical benefit was 
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variable with significant attenuation of clinical and pathological changes evident only in 
the B10.D2→BALB/c model.    
 
Materials and methods   
Mice: For the BO model, C57Bl/6 (B6; H2b) mice were purchased from the National 
Cancer Institute. B10.BR (H2k) mice were purchased from the Jackson Laboratory. For 
the BALB/c (H2d)→B10.D2 (H2d) model, mice were propagated in the animal facility at 
the Johns Hopkins University Cancer Research Building I. For the B6 
parent→B6D2F1(H2b/d) model, mice were purchased from ARC (Perth, WA, Australia) 
and used between 8-13 weeks of age. Mice were housed in a specific-pathogen–free 
facility and used with the approval of each institution’s animal care committee. 
 
Bone marrow transplantation: For the BO model, B10.BR mice were conditioned with 
Cytoxan (Sigma, 120mg/kg/day, i.p., day-3&-2) and TBI (8.3Gy, day-1), followed by 
infusion of 10×106 B6 T cell depleted bone marrow (TCD-BM) only as healthy control, 
or plus 75,000 purified splenic T cells to induce cGVHD (day0) 29,66. For the B10.D2 to 
BALB/c scleroderma model, BALB/c mice were conditioned with TBI (7.75Gy, day0), 
followed by infusion of 10×106 B10.D2 TCD-BM only or plus 1.8×106 CD4 and 
0.9×106 CD8 T cells (day0) 22. For the B6 to B6D2F1 scleroderma model, B6D2F1 mice 
were conditioned with TBI (11Gy split into 2 doses, day-1) followed by infusion of 
5×106 B6 TCD-BM only or plus 1×106 purified T cells (day0) 26. Mice were monitored 
daily, and examined at least twice a week for clinical signs of cGVHD. Assessment of 
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cutaneous GVHD in the B10.D2 to BALB/c scleroderma model was done using 
established scoring system as previously described137.  
 
Pirfenidone treatment: Pirfenidone was manufactured to Good Manufacturing Practice 
grade at SAFC Pharma (St. Louis, MO) under contract with the National Institutes of 
Allergy and Infectious Disease. The crystalline drug compound was certified to be pure 
(≥97% area by HPLC) at the University of Minnesota using a process supplied by SAFC 
Natick. The drug has been used successfully in non-human primate models of fibrosis138. 
In this study, pirfenidone crystals were ground down into fine powder using mortar and 
pestle and then suspended in 0.4% methylcellulose. Mice were given pirfenidone 
(400mg/kg) by oral gavage from day28-56 or 56-84 (BO model), day21-55 (B10.D2 to 
BALB/c model) or day14-28 or 14-41 (B6 to B6D2F1 model). Mice in the vehicle 
control group were treated with the same volume of 0.4% methylcellulose.  
 
Pulmonary function tests: Pulmonary function tests were performed as described 
previously28. Briefly, Nembutal anesthetized mice were intubated and ventilated using the 
Flexivent system (Scireq). Pulmonary resistance, elastance and compliance were 
recorded and analyzed using the Flexivent software version 5.1.  
 
Hydroxyproline assay: Mice were sacrificed by cervical dislocation. Lungs were removed 
and homogenized in 200µl de-ionized water. 100 µl aliquot of the homogenate was 
hydrolyzed in 100 µl concentrated HCL (Sigma 320331) for 3 h in 120 °C. After 
		 62	
centrifugation, 5 to 10 µl of supernatant was carefully removed to a 96-well plate and 
incubated in 56 °C oven until dry. The amount of hydroxyproline in the lung homogenate 
aliquots was measured by Hydroxyproline Assay Kit (Sigma MAK008). The result was 
adjusted to reflect hydroxyproline content in the whole sample.  
 
Histopathology and immunostaining: Lung and spleen were embedded in Optimal 
Cutting Temperature (OCT) compound, snap frozen in liquid nitrogen, and stored in -
80°C. Lungs were inflated by 75% OCT prior to harvest. For trichrome staining 8 µm 
cryosections were fixed for overnight in Bouin’s solution and stained with the Masson’s 
trichrome staining kit (Sigma HT15). Collagen deposition was quantified as a ratio of 
blue area to total area using ImageJ.  
 
For immunostaining, acetone fixed 8µm cryosections were stained with indicated 
markers. For GC detection, frozen sections of spleens were stained with rhodamine-
peanut agglutinin (PNA) and DAPI (Vector Laboratories). For macrophage and TGF-β 
staining, frozen section of lung or skin were stained with anti CD68-ef660 (FA-11, 
eBioscience 50-0681) or rabbit anti mouse F4/80/TGF-β (Abcam ab66043/ab100790) 
followed by anti-rabbit HRP-DAB staining Kit (R&D CTS005).  Confocal images were 
acquired on an Olympus FluoView500 Confocal Laser Scanning Microscope at 200X, 
analyzed using FluoView3.2 software (Olympus) and quantified by ImageJ.  
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Macrophage migration assay: J774 cells were cultured with vehicle, 0.25 or 0.5mg/ml 
pirfenidone for 24h. IL-17A (100ng/ml; eBioscience) or MCP-1/CCL2 (100ng/ml; 
GibcoTM) was added to the lower chamber as chemoattractant and J774 cells were plated 
in the upper chamber of 96 transwell plates (Corning®3374). Cells were allowed to 
migrate through the insert membrane for 4 h at 37°C under a 5% CO2 atmosphere. 
Calcein AM solution (Molecular Probes) was added to each well of receiver plate. Plates 
were incubated at 37°C in a 5% CO2 incubator for 60 minutes.  The plate was read by 
SpectraMax i3X from Molecular Devices at 485/530139.  
 
Intravascular staining and lung single cell suspension preparation: Mice were injected 
with 4 micrograms of CD45-FITC antibody (CD45 iv) (eBioscience) through tail vein 
and rested for 5 minutes before sacrificed by cervical dislocation. Lungs were removed, 
dissociated by gentleMACS dissociator (Miltenyi Biotec) and digested in collagenase D 
(2mg/ml) for 30 minutes in 37°C incubator. The digested lungs were filtered through 40 
um cell straining to create the single cell suspension. 
 
Flow Cytometry: For Tfollicular helper (Tfh) and GC B cells, single cell suspension of 
spleens was obtained and stained with fixable viability dye, fluorchrome-labeled anti-
CD4 (RM4-5, BD), anti-CXCR5 (SPRCL5, eBioscience), anti-PD-1 (J43, eBioscience), 
anti-CD19 (eBio1D3, eBioscience), anti-GL7 (GL-7, eBioscience) and anti-Fas (J02, 
BD). GC B cells were defined as Fas and GL7 double positive CD19 B cells. Tfh cells 
were defined as PD1 and CXCR5 high CD4 T cells.  Cells were analyzed on BD 
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LSRFortessa. For flow analysis of lung macrophages, single cell suspension of lung was 
stained with anti-CD45-PE (CD45 ex vivo, 30-F11, eBioscience), anti-CD11c (3.9, 
eBioscience), anti-F4/80 (BM8, eBioscience) and anti-latency associated peptide (LAP, 
TW7-16B4, eBioscience). 
 
Statistical analysis: GraphPad Prism 6 was used to conduct the statistical analysis. 
Groupwise comparisons were made by unpaired student T-test. Error bars indicated 
means +/- standard error of the mean (SEM). Significance: *P<0.05; **P<0.01; ***P< 
0.001; ****P<0.0001. 
 
Results: 
Therapeutic administration of pirfenidone reverses fibrosis in a cGVHD BO model 
To examine the efficacy of pirfenidone to reverse lung fibrosis caused by cGVHD, mice 
with BO that have systemic fibrosis with in vivo measurable fibrotic lung disease were 
treated with pirfenidone from day28-56 post-transplantation. In this model, pulmonary 
function loss and fibrotic change in the lung can be detected as early as day28, and 
progresses to day5629. The loss of lung function is detected using the FlexiVent 
(SCIREQ) system for forced oscillations measurements including resistance (increase of 
airway pressure per volume increase when the lung expands), elastance (reduction of 
airway pressure per volume reduction when the lung recoils) and compliance (increase of 
lung volume per pressure increase when the lung expands)140.  On day56, cGVHD mice 
that received BM and T cells displayed fibrotic lung disease with higher resistance and 
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elastance, and lower compliance compared with the BM only mice. Pirfenidone treatment 
from day28-56 significantly reduced lung fibrosis (P<0.01) to comparable lung function 
with BM only mice (Figure 1A).  
 
To document pirfenidone’s effect on lung fibrosis, we measured hydroxyproline levels in 
the lung, which correlates with the amount of collagen - a major component of fibrotic 
tissue. The hydroxyproline level in cGVHD group lungs is ~2-fold higher than the non-
cGVHD group, and pirfenidone treatment significantly reduced lung hydroxyproline 
content (p< 0.01) (Figure 1B), consistent with pulmonary function tests. In addition, 
Masson’s trichrome staining that identifies collagen by blue staining in tissue section was 
performed. Mice in cGVHD group showed increased collagen deposition in the 
peribronchial and perivascular areas of lung and liver compared with BM only group; 
pirfenidone treatment significantly reduced collagen deposition in lung (p<0.01) and liver 
(p< 0.05) (Figure 1C, quantified in Figure 1 D and E). Taken together, these results 
showed that pirfenidone reversed lung fibrosis caused by cGVHD.  
 
Pirfenidone reduces F4/80+ macrophage accumulation and TGF-β deposition in 
lung  
Pirfenidone inhibits TGF-β signaling pathway128,129,132,141 that contribute to tissue 
fibrosis81. TGF-β is preferentially produced from mononuclear cells following stem cell 
transplantation82, including macrophages, that are potent TGF-β producers and required 
to induce cutaneous cGVHD model26. TGF-β recruits circulating fibrocytes and 
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inflammatory cells to the sites of tissue damage and induces the expression of fibrogenic 
cytokines (e.g. PDGF and IL-13) as well as transcriptionally activates the collagen gene. 
In B10.D2→BALB/c scleroderma model, TGF-β neutralization from day14 after allo-
HSCT attenuated histologic abnormalities82. Depleting tissue macrophages by antibody 
reversed pulmonary fibrosis in the BO model26.  
 
To evaluate whether pirfenidone reduces macrophage infiltration and TGF-β production 
in the lung of cGVHD mice, serially sectioned slides of lung were stained with Masson’s 
trichrome stain, anti-F4/80 antibody and anti-TGF-β antibody (Figure 2A). Macrophage 
and TGF-β staining were significantly increased in the cGVHD lungs (Figure 2B&C). 
The peribronchial and perivascular areas stained strongest and these are also the areas 
where extensive collagen deposition occurred, suggesting macrophages and TGF-β are 
mediators in cGVHD pathogenesis.  Notably, pirfenidone treatment significantly reduces 
both macrophage and TGF-β in the lung.  
 
To understand whether pirfenidone inhibits TGF-β production from macrophage, cGVHD 
mice were treated with pirfenidone from day28-35 and lung cells were analyzed by flow 
on day36. Due to the failure of lung perfusion to completely remove blood cells from 
lung vasculature142, thus causing difficulties in discriminating tissue and blood-borne 
macrophages in the lung, we used intravascular CD45 antibody staining (CD45 iv) to 
identify blood-borne macrophages before mice were sacrificed143. Tissue macrophages 
are defined as F4/80+CD11c-CD45iv- cells and alveolar macrophages are defined as 
		 67	
F4/80+CD11c+ cells144 (Supplementary Figure 1). LAP, a protein that is contained in 
TGF-β precursor at the N-terminus, was quantified for assessment of TGF-β surface 
expression145. LAP expression in both alveolar and tissue macrophages was increased 
significantly in the cGVHD mice, consistent with immunohistochemistry staining as 
above, and pirfenidone reduced LAP expression on both alveolar and tissue macrophages 
(Figure 2D-E). These results suggest that the reduced TGF-β production in lung by 
pirfenidone was due to a combined effect of reduced macrophage number and reduced 
TGF-β producing capacity of macrophages.  
 
Activated macrophages are generally categorized into classically (M1) and alternatively 
(M2) activated phenotypes. M2 macrophages are crucial for wound healing, fibrosis and 
anti-inflammatory effects, while M1 macrophages are more important for pro-
inflammatory effects. To determine the phenotype and origin of the infiltrating 
macrophages in the lung, we used CD45.1 B6 donors and stained the lungs of cGVHD 
mice with donor marker (CD45.1) and the M2 macrophage marker CD206, together with 
the macrophage marker CD68. Immunofluorescence staining showed that the majority of 
CD68+ cells are also CD45.1+ and CD206+ (Figure 2F), suggesting that infiltrating 
macrophages in cGVHD are donor BM-derived and are M2 phenotype. M2 macrophage 
infiltration has also been observed in several scleroderma cGVHD models and is required 
for pathogenesis26.  
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Since pirfenidone reduces macrophage infiltration in nephrectomized rats146, inhibits 
monocyte chemoattractant protein-1 (MCP-1/CCL2) in a bleomycin induced lung fibrosis 
model132, and reduces macrophage infiltration into the lungs of cGVHD mice, we sought 
to further evaluate pirfenidone’s effect on macrophage migration. For this purpose, a 
transwell assay was used. IL-17A and MCP-1 were chosen as chemoattractants147 based 
on their implications in cGVHD pathogenesis in this37 and other transplant 
settings28,38,39,148–151. Pirfenidone significantly inhibited both IL-17A and MCP-1 induced 
J774 macrophages migration in vitro (Figure 2G). Taken together, these results suggest 
that cGVHD lung disease is mediated by donor M2 macrophage infiltration and excessive 
TGF-β production, and that pirfenidone not only inhibits IL-17A facilitated macrophage 
infiltration, but also macrophage TGF-β production.  
 
Pirfendone reduces the GC reaction in cGVHD mice 
cGVHD pathogenesis in the BO model requires auto/allo antibodies production driven by 
elevated GC reaction29,66. Previously, we showed that cGVHD mice develop a 
spontaneous GC reaction reflected by increased size and frequency of splenic GCs and 
increased frequency of GC B cells and Tfh cells in cGVHD mice compared with BM 
only mice; further disrupting the GC reaction can ameliorate cGVHD in this model66. To 
examine whether pirfenidone interferes with this pathological process, we evaluated the 
effect of pirfenidone on the GC reaction. While GCs were significantly upregulated in 
cGVHD mice as indicated by GC B cell (Figure 3A&B) and Tfh cell (Figure 3C&D) 
frequencies, as well as by GC size (Figure 3E &F) and number (Figure 3G), pirfenidone 
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treatment significantly impaired these immunological effects. These results suggest that 
pirfenidone inhibits a known driving force of cGVHD pathogenesis.  
 
The magnitude of GC reaction can be affected by both the function and quantity of 
required Tfh and GC B cells, and the availability of antigen152. Pirfenidone has been 
reported to suppress alloresponses in heart allograft recipients by suppressing T cell 
function153. To assess whether pirfenidone could directly affect the GC reaction in a non-
cGVHD setting, we used a sheep red blood cell (SRBC) immunization model. Mice were 
immunized with SRBC to induce GC reactions on day0. In the pirfenidone treatment 
group, mice were treated with pirfenidone from day-1 to day6. On day7, spleens and 
serum were harvested for GC reaction evaluation and SRBC antibody detection. 
Interestingly, pirfenidone did not affect the magnitude of the GC reaction induced by 
SRBC, as indicated by comparable frequencies of GC B cells and Tfhs in pirfenidone 
treated and vehicle-treated groups (Supplementary figure 2A&B). There was no 
difference in the SRBC-specific antibody concentration between pirfenidone treated and 
vehicle treated groups (Supplementary figure 2C). These results suggest that pirfenidone 
interferes with cGVHD-specific antigen responses or the amplification of such responses 
that lead to the GC reaction rather than by globally suppressing GC formation in response 
to a potent GC inducing stimulus such as SRBCs. 
 
Pirfenidone treatment has a long-lasting effect and is capable of reducing later stage 
disease 
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To determine whether pirfenidone inhibition of pulmonary fibrosis was transient, 
transplanted mice were treated with pirfenidone day28-56 after transplantation and were 
left untreated for 28 days before pulmonary function tests were performed. Day84 
pulmonary function tests of mice treated with pirfenidone for 28 days and rested for 
another 28 days were still significantly better than for mice that never received treatment, 
although not reaching the levels of BM only mice (Figure 4A). Thus, pirfenidone has a 
long-lasting effect on cGVHD fibrosis.  
 
To evaluate the efficacy of pirfenidone in a late stage of cGVHD, transplanted mice were 
treated from day56-84 after transplantation. Day84 pulmonary function tests indicated 
that pirfenidone reduced lung disease even at this later stage of the disease process 
(Figure 4A). Hydroxyproline assay (Figure 4B) and trichrome staining (Figure 4C-E) 
correlated with pulmonary function test results. Taken together, these results highlight the 
potential of pirfenidone to be an option for patients with established disease who cannot 
tolerate continuous treatment.  
 
Pirfenidone treatment has variable efficacy in the scleroderma models  
To examine whether pirfenidone can also attenuate skin fibrosis, we used 2 different skin 
cGVHD models. In the minor histocompatibility antigen-mismatched B10.D2 to BALB/c 
model, dermal fibrosis is dependent on both Th1 and Th17 CD4+ T cells22 and preceded 
by infiltration of donor-derived CD11b+ cells consisting of monocytes and activated 
macrophages154. Clinical skin disease in this model develops ~day20 after 
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transplantation137,  thus pirfenidone treatment was started on day21 when clinical disease 
is already established in the majority of animals. Pirfenidone reduced skin lesion, as 
showed by reduced clinical and histological scores (Figure 5A&B). While the 
profoundness of pirifenidone’s effects on the skin scores varied between the experiments, 
the drug effect on the reduction of collagen deposition and macrophage infiltration in 
cGVHD mice was consistently observed (Figure 5C&D). In the B6 to B6D2F1 
haploidentical transplant model, F4/80 macrophage infiltration in the dermis is noted by 
day21 post-transplantation, and becomes localized in the subcutaneous fat layers. 
Infiltrated macrophages are donor BM-derived M2 macrophages and dependent on CSF-
1 signaling. Pirfenidone treatment from day14-28 marginally but significantly decreased 
day28 macrophage infiltration but this was insufficient to translate to reductions in 
cutaneous pathology (Figure 5E). 
 
Discussion  
cGVHD patients have manifestations that are similar to fibrotic diseases such as systemic 
sclerosis and idiopathic pulmonary fibrosis155. Thus, anti-fibrosis treatments may offer a 
novel therapeutic approach for cGVHD patients. Although preclinical studies have shown 
that neutralization of TGF-β reduces skin fibrosis and gastrointestinal GVHD scores in 
the B10.D2→BALB/c cGVHD model23,25,82, there is no anti-fibrosis drug available for 
cGVHD patients. Here, we demonstrated the efficacy of pirfenidone, an FDA approved 
drug for idiopathic pulmonary fibrosis, in reversing fibrosis in the multi-organ system, 
BO cGVHD model previously demonstrated to mimic several aspects of human cGVHD, 
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with the exception of sclerodermatous cGVHD29. Pulmonary function and pathological 
changes in the cGVHD lung were normalized by pirfenidone when treatment was begun 
at one month post-transplant, while improving but not completing reversing disease when 
delayed an additional month to day56 post-transplant. These results extend other studies 
showing that pirfenidone can reduced lung fibrosis in bleomycin- and lung allograft 
rodents models129,130,132,156. The protective effect of pirfenidone is associated with a 
decrease of infiltrating macrophages surrounding the bronchioles and a decrease of TGF-
β production by these macrophages. Since BO is also a major problem in lung 
transplantation, the current finding in BO cGVHD model may also shed light on the 
management of lung transplantation complications. 
 
Pirfenidone is a small molecule that is rapidly absorbed and metabolized into 5-carboxy-
pirfenidone, whose anti-fibrotic effect is weaker than that of pirfenidone157. Pirfenidone’s 
pharmacokinetics and metabolism profile have be characterized by Buckpitt et al158, 
showing that after administration, the peak level of pirfenidone in tissues correlates with 
the degree of tissue penetration. Whereas pirfenidone alleviated skin fibrosis in 2 clinical 
trials for localized scleroderma and burn injury135,159, in both scleroderma models tested 
here, pirfenidone had a variable and modest effect under the conditions tested, although a 
significant reduction in macrophage infiltration was observed in both models. The 
relative modest or absence of effect of pirfenidone on skin manifestations may be 
attributable to the fact that skin is not perfused as well as other organs where pirfenidone 
has a more evident effect such as lung and liver. In addition, rapid onset of skin scarring 
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may further limit the access of pirfenidone to its target sites. Since scleroderma in the 
B6àB6D2F1 haploidentical is known to be macrophage dependent26, the lack of clinical 
and pathological improvement was unexpected. We hypothesize that the failure of 
pirfenidone to completely eliminate macrophage infiltration into the skin, perhaps due to 
tissue penetration may account for the inability of pirfenidone treatment in these systemic 
scleroderma models to reverse established disease. Thus, topical treatment of pirfenidone 
in scleroderma cGVHD models warrants testing in the future.  
 
The cGVHD BO model depends on antigen-activated GC reactions that result in antibody 
deposition in multiple organs including lung and liver that trigger pro-fibrotic responses. 
This feature of the BO model mimic human cGVHD, as autoreactive antibodies have 
been identified in cGVHD patients160. In addition, antibodies against Y-chromosome 
encoded antigens have been identified in male patients transplanted with BM from female 
donors44. Although as discussed above, pirfenidone is well known for its anti-fibrosis 
ability, pirfenidone also has been reported to suppress allo-responses161. By using a 
cGVHD independent SRBC immunization model, we showed that pirfenidone does not 
directly regulate GC reactions as pirfenidone treated mice still developed strong GC 
responses against SRBC immunization. Rather than a direct effect of pirfenidone on the 
GC reaction, pirfenidone may be influencing the GC response via macrophages that are 
known to be required for cGVHD in the BO cGVHD model26. These data pointed to the 
capacity of pirfenidone to modify the particular antigen-driven response for cGVHD 
generation and maintenance. Wilkes and colleagues have shown that IL-17-dependent 
		 74	
immune responses against collagen V contribute to BO in preclinical and clinical lung 
transplant settings162–164. In rheumatoid arthritis, immune responses against collagen also 
may contribute to disease. As collagen content is significantly increased in cGVHD mice 
and reduced by pirfenidone treatment, we hypothesize that pirfenidone may be 
ameliorating disease by reducing IL-17A facilitated macrophage infiltration, macrophage 
TGF-β production and hence collagen production147, especially based on its implication 
in cGVHD pathogenesis in this37 and other cGVHD settings38,39,149–151.  Consistent with 
this hypothesis, we directly demonstrate that pirenidone impedes macrophage migration 
to IL-17A in vitro and lung macrophage infiltration in a cGVHD system that is dependent 
upon IL-17A for disease generation37. Pirfenidone also impaired macrophage migration 
to MCP-1/CCL2. Although in sclerodermatous cGVHD, some studies have shown MCP-
1 to be upregulated165 with biological responses to pravastatin treatment associated with 
MCP-1 downregulation166, whereas in another model [B6 parent→B6D2F26], MCP-1 
neither affected the development or inflammatory response. Interestingly, the latter model 
did not have a robust clinical effect in response to pirfenidone treatment. In contrast, high 
MCP-1 levels have been associated with the pathogenesis of bronchiolitis obliterans167 
and in the BO cGVHD model here, pirfenidone was highly effective in treating disease, 
which was associated with reduced macrophage infiltration in the lung. B cells in 
cGVHD patients are in a more active state given the increased B cell-activating factor/B 
cell ratio after transplantation87. In this scenario, excessive collagen can be recognized by 
hyper-responsive B cells resulting in the production of auto-antigen that then triggers the 
GC response in cGVHD recipients. Thus, the reversal of GVHD observed with 
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pirfenidone treatment also may be attributed to the reduction of collagen as an 
autoantigen. Understanding the mechanism of action for this effect requires further 
experimentation. 
 
In conclusion, we identify here the utility of pirfenidone in treating BO cGVHD and in 
reducing macrophage infiltration in cGVHD target organs including the lung and the 
skin. Our studies provide a rationale for the of topical pirfenidone for sclerodermatous 
cGVHD and consideration of future clinical trials for pirfenidone as cGVHD therapy in 
patients, particularly those that have BO, a devastating complication of allo-HSCT136.   
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Figure Legends 
Figure 1. Therapeutic administration of pirfenidone reverses fibrosis in cGVHD BO 
model 
B10.BR mice were conditioned with cytoxan (120mg/kg/day, i.p., day-3 & -2) and total 
body irradiation (8.3 Gy, day-1), followed by infusion of 107 B6 T cell depleted bone 
marrow only as healthy control, or plus 75,000 purified splenic T cells to induce cGVHD 
(day0). In the treatment group, cGVHD mice received pirfenidone (400mg/kg) from 
day28 to day56. (A) Pulmonary function tests on day56 post-transplantation showed that 
pirfenidone restored lung function of cGVHD mice. Data are representative of 3 
experiments with similar results. (B) Hydroxyproline assay of the right lungs harvested 
on day56 indicated that pirfenidone significantly reduced hydroxyproline content. 5-6 
mice from each group were analyzed. Data are representative of 2 experiments with 
similar results. (C) Representative images of Masson’s trichrome staining images of lung 
(upper) and liver (lower). Collagen (blue stain) was quantified in (D) and (E). (F&G) 
Representative lung Ig deposition images and quantification. Data are representative of 2 
experiments with similar results.  *p ≤ 0.05, **p < 0.01; ***p < 0.001; data are shown as 
the mean plus or minus standard error of the mean. 
 
Figure 2. Pirfendone reduces F4/80+ macrophage accumulation and TGF-β 
deposition in lung  
(A-C) Serial sections of lungs harvested on day56 post-transplantation were stained with 
trichrome staining (A, top panel), anti-F4/80 antibody (A, middle panel) and anti-TGF-β 
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antibody (A. bottom panel). F4/80 positive cell number and TGF-β staining area were 
quantified in (B) and (C). Pirfenidone reduced macrophages infiltration and TGF-β 
production in lung. (D&E) Mice were transplanted as described in Figure 1. cGVHD 
mice were treated by pirfenidone for a week from day28-35. On day35, LAP expression 
in alveolar macrophages (D) and tissue macrophages (E) were analyzed by flow 
cytometry. Pirfenidone significantly reduced LAP expression in both alveolar and tissue 
macrophages. (F) Donor B6 mice are CD45.1 and B10.BR CD45.2 recipient mice were 
used. Lung sections were fixed and stained with anti-CD45.1 (donor marker, red), CD68 
(grey) and CD206 (green). Arrows pointed at cells that are CD45.1+CD68+CD206+. This 
result suggests that infiltrating macrophages in the lung are donor derived M2 
macrophages. (G) Macrophage migration was assessed in a transwell assay. IL-17A or 
MCP-1was used as chemoattractants to induce migration. Pirfenidone (0.25 or 0.5mg/ml) 
or vehicle was added to cell culture medium and migration medium. Pirfenidone 
inhibited IL-17A and MCP-1 induced J774 migration. 5-8 mice were analyzed for each 
group in each assay. Results are representative of at least 2 experiments with similar 
results. Migration assay result is representative of 3 experiments with similar results. *p ≤ 
0.05, **p < 0.01; ***p < 0.001; data are shown as the mean plus or minus standard error 
of the mean. 
 
Figure 3. Pirfendone reduces the GC reaction in cGVHD mice 
Spleens were harvested on day56 post-transplantation. Splenocytes were stained with 
fluorochrome labeled antibodies against CD4, CD19, FAS, GL4, CXCR5 and PD1. Fixed 
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spleen sections were stained with GC B cell marker PNA and DAPI.  (A-D) 
Representative flow cytometry plots of GC B cells (FAS+GL7+) (A) and Tfh cells 
(PD1hiCXCR5+) (C) in splenocytes. Cells were gated on live CD19 cells and CD4 cells, 
respectively. Quantification of GC B cell and Tfh cell frequency were showed in (B) and 
(D). Results were pooled from 2 independent experiments with 5-8 mice per group. (E) 
Representative GC immunofluorescence staining images of the spleens. (F) Size of GCs 
in the spleen. 5-6 GCs from each mouse were photographed and size was measured. 5-6 
mice from each group were analyzed. Data are representative of 2 independent 
experiments with similar results. (G) Frequency of GC in the spleen. The number of GCs 
in each spleen was divided by the size of the spleen section. 5-6 mice from each group 
were analyzed. Data are representative of 2 independent experiments with similar results. 
*p ≤ 0.05, **p < 0.01; ***p < 0.001; data are shown as the mean plus or minus standard 
error of the mean. 
 
Figure 4. Pirfenidone treatment results in long-lasting effects and is able to reduce 
later stage disease  
Mice were transplanted as in Figure 1. Mice were untreated or treated, as indicated, with 
pirfenidone from day28-56 or day56-84. All the mice are evaluated on day84. (A) 
Pulmonary function tests on day84 showed that pirfenidone effects were significant even 
4 weeks after treatment cessation. Additionally, pirfenidone treatment was effective even 
when treatment started at late-stage (day56) of the disease. (B) Hydroxyproline assay 
correlated with pulmonary function test result. (C) Masson’s Trichrome staining of lung 
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and liver. (D&E) Quantification of trichrome staining area in the lung and liver. 5-8 mice 
were analyzed for each assay. *p ≤ 0.05, **p < 0.01; ***p < 0.001; data are shown as the 
mean plus or minus standard error of the mean. 
 
Figure 5. Pirfenidone treatment shows variable efficacy in the scleroderma models  
(A-D) BALB/c mice were conditioned with TBI (7Gy, day0), followed by infusion of 107 
B10.D2 BM only or plus 1.8 x106 CD4 and 0.9 x106 CD8 T cells (day0). In the treatment 
group, mice were treated with pirfenidone from day21-55. (A) Skin clinical score based 
on the area of skin lesion. (B) HE staining of the skin (left) and pathology score (right). 
Pirfenidone reduced both clinical score and pathology score. (C) Trichrome staining of 
skin. Collagen was stained blue. Fibrosis was scored on a 1-5 scale based on the intensity 
of blue staining. Pirfenidone significantly reduced collagen deposition in skin. (D) 
Immunofluorescence staining of macrophage in skin samples. CD68 (red) identified 
macrophages. Pirfenidone significantly reduced macrophage infiltration in skin. (E) Flow 
cytometry analysis cytokine production and Treg percentage of splenocytes from 
transplanted mice. (F) B6D2F1 mice were conditioned with TBI (11 Gy split into 2 doses, 
day-1) followed by infusion of 5 × 106 B6 BM only or plus 1 × 106 purified T cells 
(day0). Where indicated, mice were treated with pirfenidone from day14-28 or day14-41. 
HE staining on day28 (top) & 42 (bottom) and day28 F4/80 staining (middle) indicating 
that pirfenidone alleviated macrophage infiltration but failed to significantly improve 
pathological changes. In each experiment, 5-10 mice from each group were tested. *p ≤ 
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0.05, **p < 0.01; ***p < 0.001; data are shown as the mean plus or minus standard error 
of the mean. 
 
Supplementary figure 1. Intravascular staining and gating strategy of lung flow 
cytometry analysis  
(A) Flowchart of intravascular staining: Mice were injected with 4 micrograms of CD45-
FITC antibody (CD45 iv) through tail vein and rested for 5 minutes before sacrificed by 
cervical dislocation. Blood and lymph nodes were collected. Lungs were removed, 
dissociated by gentleMACS dissociator (Miltenyi Biotec) and digested in collagenase D 
(2mg/ml) for 30 minutes in 37°C incubator. The digested lungs were filtered through 40 
um cell straining to create the single cell suspension. Lung cells were stained with CD45-
PE (CD45ex vivo) together with other markers of interested. Blood lymphocytes cells are 
CD45iv+ CD45ex vivo+, while lymphocytes in lymph nodes are CD45iv- CD45ex vivo+. 
(B) Gating strategy used to identify tissue macrophages and alveolar macrophages in the 
lung. Tissue macrophages are identified as CD45ex vivo+F4/80+CD11c-CD45ivlow cells. 
Alveolar macrophages are identified as CD45ex vivo+F4/80+CD11c+ cells.  
 
Supplementary figure 2. Macrophage deficient and sufficient donor grafts have 
comparable GVL effects. 
B6D2F1 recipients were conditioned with TBI (11 Gy split into 2 doses, day-1) followed 
by infusion of 5 × 106 B6 BM from either B6 WT FLC or CSF1R–/–FLC only or plus 1 × 
106 purified T cells (day0). 0.1 × 106 MLL-AF9-GFP leukemia cells were infused on day 
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0. (A) Survival curve suggests that WT and CSF1R–/– donor bone marrow had similar 
GVL responses. (B) Blood leukemia cell counts determined by GFP staining suggest that 
CSF1R-/- BM recipients have similar GVL effect on day  7 and day 30 to WT BM 
recipients. 
 
Supplementary figure 3. Pirfenidone treatment does not impair the GC reaction 
induced by SRBC immunization  
Naïve B6 mice were immunized with SRBC or PBS. In the treatment group, mice were 
with Pirfenidone from day-1 to day7 after immunization. Flow analysis of GC B cell (A) 
and Tfh cell frequencies showed that pirfenidone didn’t suppress germinal center reaction 
induced by SRBC. (C) Serum concentration of anti-SRBC antibody analyzed by ELISA 
correlated with flow results. In each experiment, 5-10 mice were tested. *p ≤ 0.05, **p < 
0.01; ***p < 0.001; data are shown as the mean plus or minus standard error of the mean. 
 
Supplementary figure 4. Pirfenidone suppresses Tcon proliferation but does not 
affect Treg suppressive function.  
Tregs were isolated from naïve B6 mice, conventional CD4 T cells (Tcon) and antigen 
presenting cells (APCs) were isolated from the spleen of C57BL/6-Ly5.1 mice expressing 
CD45.1. Tcons were labeled with CFSE and stimulated in 0.25 microgram/ml anti-CD3. 
(A) Treg and Tcons were mixed at indicated ratio. APC were added to the system. Cells 
were cultured for 3 days with Pirfenidone or vehicle. (B) Treg were pre-treated with 
pirfenidone or vehicle for 1h and washed to remove residual pirfenidone. Tcon were 
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mixed with Treg at 3:1 ratio. CFSE dilution was analyzed by flow cytometry. Pirfenidone 
suppresses CD4 proliferation but does not inhibit Treg suppressive function.   
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Chapter 5 Murine chronic graft-versus-host disease proteome profiling discovers 
CCL15 as a novel druggable biomarker in patients 
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Abstract 
Improved diagnostic and treatment methods are needed for chronic graft-versus-host 
disease (cGVHD), the leading cause of non-relapse mortality (NRM) in long-term 
survivors of allogenic hematopoietic cell transplantation (allo-HCT). Validated 
biomarkers that facilitate disease diagnosis, classification and prognosis generally are 
lacking in cGVHD. Here, we conducted whole serum proteomics analysis of a well-
established murine multi-organ system cGVHD model. We discovered 4 up-regulated 
proteins during cGVHD that are targetable by genetic ablation or blocking antibodies, 
including the RAS and JUN kinase activator, CRKL, and CXCL7, CCL8 and CCL9 
chemokines. Donor T cells lacking CRK/CRKL prevented the generation of cGVHD, 
germinal center reactions and macrophage infiltration seen with wild-type T cells. 
Whereas antibody blockade of CCL8 or CXCL7 was ineffective in treating cGVHD, 
CCL9 blockade reversed cGVHD clinical manifestations, histopathological changes and 
immunopathological hallmarks. Mechanistically, elevated CCL9 expression was present 
predominantly in spleen vascular smooth muscle cells and uniquely seen in cGVHD 
mice. Importantly, plasma concentrations of CCL15, the human homologue of mouse 
CCL9, were elevated when analyzed in a previously published, well-defined cohort of 
211 cGVHD patients compared to controls. High CCL15 levels were associated with high 
NRM. Our findings demonstrate for the first time the utility of preclinical proteomics 
screening to identify potential new targets for cGVHD and specifically CCL15 as a 
marker for cGVHD diagnosis. Successful anti-CCL9 treatment of established murine 
cGVHD coupled with cGVHD patient CCL15 elevation in a retrospective analysis 
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warrants prospective biomarker validation studies and, if confirmed, consideration for 
CCL15 blockade testing in human cGVHD therapeutic trials. 
 
Introduction 
Chronic GVHD occurs in approximately 30-50% of allo-HCT patients and is the leading 
cause of late morbidity, mortality and non-relapse mortality (NRM)168–172. Despite 
advances in the understanding of the pathobiology of cGVHD31,173, clinical management 
of cGVHD remains challenging. Standard treatment for cGVHD relies on non-selective 
systemic immune suppression, which may render the patients susceptible to infection and 
relapse of primary malignancy. The diagnosis of cGVHD depends largely on clinical 
examinations following the National Institute of Health (NIH) diagnosis criteria 174,175. 
Early diagnosis of cGVHD is crucial for disease management but is complicated by 
factors such as variations of time and site of disease onset, lack of fully distinctive 
manifestations in the early stage, overlapping symptoms with acute GVHD and lack of 
qualified biomarkers176,177.  
 
There has been increasing interest in identifying cGVHD biomarkers, driven by the 
applications in diagnosis, prognosis, disease stratification and guiding treatment 
strategies176,178. Different types of biomarkers have been identified. For example, B cell 
activating factor (BAFF) plasma levels prior to or at cGVHD diagnosis were associated 
with subsequent cGVHD and NRM, respectively56,179. Regulatory T cells (Treg) have 
been inversely correlated with cGVHD severity180 and incidence181 and may be used for 
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cGVHD early diagnosis182 and prediction183. The majority of published biomarkers are 
generated from hypothesis-driven studies where a putative causative factor was 
specifically quantified. This method is limited by current knowledge regarding cGVHD 
pathogenesis. In contrast, proteomics analysis is an non-biased strategy to study the broad 
spectrum of differentially expressed proteins from disease and control individuals, which 
has proven useful in identifying new biomarkers150,177,184. Using this strategy, researchers 
has discovered that plasma matrix metalloproteinase-3 (MMP-3) is associated with lung 
cGVHD185, manifested as a bronchiolitis obliterans (BO) syndrome, the most lethal form 
of cGVHD. In other studies, a pattern of 14 differently secreted peptides in urine allowed 
for early and accurate prediction of cGVHD186.  
 
Although allo-HCT patients have been the major target of cGVHD biomarker studies, 
significant heterogeneity due to distinct biological and/or clinical profiles can impede the 
discovery of new biomarkers176. On the other hand, mouse models using inbred strains 
housed in a specific-pathogen free facility and studied contemporaneously present an 
opportunity to study a more homogeneous biology without as many confounding clinical 
and temporal variations121.  
 
In this study, we conducted full spectrum proteomic analysis of serum samples from a 
well-established murine multi-organ system cGVHD model that incorporates clinically 
relevant regimens and develops auto/allo immune responses and systemic fibrosis 
including of BO. Using high throughput, discovery-based Mass Spectrometry (MS) 
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technique, we identified 4 potential biomarkers of cGVHD, of which CCL15 proved 
druggable and was verified in highly characterized and previously reported patient 
cohorts.  
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Materials and methods 
Mice  
C57Bl/6 (B6; H2b) mice were purchased from the National Cancer Institute and used at 
8-12 weeks old. B10.BR (H2k) mice were purchased from the Jackson Laboratory and 
used at 10-14 weeks old. Mice homozygous for both floxed Crk and Crkl genes were 
crossed with Cd4-Cre transgenic mice on the C57BL/6 background (Taconic) to generate 
Crk/Crkl-/- T cells187,188. Animal protocols were approved by Institutional Animal Care 
and Use Committee at the University of Minnesota.  
 
Induction of cGVHD 
B10.BR mice were conditioned with intraperitoneal Cytoxan (Sigma, 120mg/kg/day, i.p., 
day-3&-2) and total body irradiation (8.3 Gray, day-1), followed by infusion of 107 B6 T 
cell depleted bone marrow (TCD-BM) only as non-cGVHD control, or plus 70,000 
purified splenic T cells to induce cGVHD (day 0), purified as described29,66.  
 
Pulmonary Function Tests 
cGVHD was assessed by pulmonary function tests on day 56 ± 4 days as previously 
described29,66.   Nembutal anesthetized mice were intubated and ventilated using the 
Flexivent system (Scieq). Airway resistance, elastance and compliance were recorded and 
analyzed using the Flexivent software version 5.1.  
 
Serum collection for murine proteomics 
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Mice were first anesthetized using a ketamine/xylazine mix. An intracardiac puncture was 
performed using a 27G needle and 1 mL syringe from the right ventricle. Blood was 
directly transferred into a dry Eppendorf tube on ice for 30 min then spun at 2000g for 
10-15 min. Serum was collected and frozen at -80°C until day of use (only one freeze-
thaw cycle was permitted).  
 
Proteomics  
Sample preparation and protein fractionation 
Each pool contained 100 µl of serum. The two pooled serum samples were then 
individually immunodepleted of the 3 common hyper-abundant proteins (albumin, IgG, 
and transferrin) with a Multi Affinity Removal Column (MARS) 4.6 x 50 mm (Agilent) 
according to manufacturer’s protocol.  After measuring protein concentrations of depleted 
serum with a Micro BCA protein assay reagent kit (ThemroFisher Scientific), the volume 
of 100 µg aliquots were reduced to approximately 1/10 using Vivaspin® 500 
(Vivaproducts) and precipitated using acetone at -20°C overnight. After centrifugation for 
25 minutes at 15,000×g, acetone was decanted, and the air-dried protein pellets were 
dissolved in 100 µL of 8 M urea.  Each sample was reduced by adding 50 µL of 10 mM 
dithiothreitol (DTT) in 100mM ammonium bicarbonate and incubated for 45 min at 
56°C.  The cysteine residues were alkylated by adding 30 µL of 50 mM iodoacetamide in 
100mM ammonium bicarbonate to each vial and incubating for 30 minutes in darkness.  
Additional 30 µL of 10 mM DTT in 100mM ammonium biarbonate was added to 
neutralize iodoacetamide, and all solutions were diluted with 50 mM ammonium 
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bicarbonate to 1M urea concentration.  All samples were trypsinized by adding 2 µg of 
trypsin (Promega) in 20 µL of 50 mM ammonium bicarbonate to each and incubating 
them overnight at 37°C. Each sample was diluted further with 0.1% TFA to 800 µL and 
cleaned using Oasis HLB 10mg cartridge (Waters). The cartridges were conditioned with 
1 mL acetonitrile, 2 × 1 mL 65% acetonitrile 0.1% TFA in water, and 2 × 1 mL 0.1% 
TFA. After sample loading and washing 2 × 1 mL 0.1% TFA, peptides were eluted using 
1 mL of 65% acetonitrile and 0.1% TFA in water and dried in a speed vac. Each sample 
was then labeled with a unique tag allowing for differential quantification. The dried 
peptides were dissolved in 100 µL of 200mM HEPES, pH8.5.  41 µL of acetonitrile was 
added to 0.8 mg each of TMT reagent, 126 and 127 (Thermo Scientific).  The samples 
were labeled in the following order: 1) control (bone marrow (BM) only) with label 126, 
and 2) cGVHD (BM and T cells) with label 127. 40 µL out of 41 µL TMT solution was 
then added to each sample vial, and the vials were incubated at room temperature for 1 
hour. The labeling reaction was quenched by adding 8 µL hydroxlamine in water. All 
vials were dried in a speed vac separately, re-dissolved in 0.1% TFA, combined, and 
cleaned with Oasis HLB 10mg cartridge (Waters) as before.  The dried TMT labeled 
peptide sample was stored at -20°C until fractionation by strong cation-exchange (SCX) 
chromatography. 
  
The sample was dissolved in buffer A (7mM potassium phosphate, 30% acetonitrile, pH 
2.65) before fractionation with a SCX column (polySULFOETHYL A, 5 µm, 2.1 × 100 
mm, PolyLC). Fractions were collected at 1 minute intervals at a flow rate of 200 µL/min 
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from 1% solvent B (7 mM potassium phosphate, 500 mM KCl, 30% acetonitrile, pH 
2.65) to 60% over 40 min (1% B for 7 minutes, 6–15% B for 23 min, 15–34% B for 15 
min, and 34–60% B for 10 min) as well as during column washing with 98% solvent B 
for 10 min. The chromatographic elution was monitored using a UV detector at λ=220 
nm. These fractions were consolidated into 12 fractions using the UV trace to distribute 
the peptide quantities similarly. After drying them in a speed vac, peptides were desalted 
with Oasis HLB 10mg cartridge (Waters) as before and dried in a speed vac.   
 
LC-MS/MS analysis 
LC-MS/MS analysis was performed with an Easy-nLC 1000 (Thermo Scientific) coupled 
to an Orbitrap Fusion mass spectrometer (Thermo Scientific). The LC system configured 
in a vented format189 consisted of a fused-silica nanospray needle (PicoTip™ emitter, 75 
µm ID, New Objective) packed in-house with 25 cm of Magic C18 AQ 100Å reverse-
phase media (Michrom Bioresources Inc.), and a trap (IntegraFrit™ Capillary, 100 µm 
ID, New Objective) containing 2 cm Magic C18 AQ 200Å. The peptide sample was 
diluted in 30 µL of 2% acetonitrile and 0.1% formic acid in water, and injection volumes 
ranging between 1-4 uL were loaded onto the column in triplicate and separated using a 
two-mobile-phase system consisting of 0.1% formic acid in water (A) and 0.1% formic 
acid in acetonitrile (B). A 90-min gradient from 7% to 30% B at a flow rate of 400 
nL/min was used for chromatographic separation. The mass spectrometer was operated in 
a data-dependent MS/MS mode over the m/z range of 400–1500. The precursor scan 
mass resolution was set to 120,000.  The cycle time was set to 3 seconds, and the most 
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abundant ions from the precursor scan were isolated for MS/MS analysis using a 
quadrupole with 1.6 (m/z) mass window, dissociated with 37% normalized HCD collision 
energy and analyzed with an orbitrap with the resolution set to 60,000. Selected ions were 
dynamically excluded for 30 seconds.   
 
Peptide and protein identification from mass spectra of digested fragments 
Proteome Discoverer™ version 2.1 was used for data analysis. The acquired LC-MS/MS 
data were data were searched against the Swiss-Prot mouse proteome database (August 4, 
2015) using SEQUEST190 with the following parameters: trypsin was set as the digestion 
protease, with 2 maximum missed cleavages; precursor and fragment error tolerance were 
10 part per million (ppm) and 0.6 Dalton, respectively; Tandem Mass Tag™ (TMT) 
modification of N-termini was a fixed modification; and TMT modification of lysine 
residues, carbamidomethyl on cysteine residues, and oxidation of methionine residues as 
variable modifications. Identified peptides were filtered according to a 1% peptide-level 
false discovery rate (FDR) using Percolator191. Proteins with at least one identified 
peptide were reported. Ratios were normalized to the median of all PSMs (Peptide 
Spectrum Match). 
 
The mass spectrometry proteomics data have been deposited in the ProteomeXchange 
Consortium192 via the PRIDE partner repository with the dataset identifier PXD00627. 
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Candidate biomarker selection   
This study was designed to discover and validate biomarkers by profiling the proteome of 
murine cGVHD sera then validating the cause-and-effect relationship for those 
preferentially elevated in cGVHD mice by using donor cells from relevant knockout mice 
or infusing neutralizing antibody to reverse established cGVHD. Four candidates (CCL8, 
CXCL7, CCL9, CRKL) were chosen for further in vivo analysis. Based on the murine in 
vivo data, three proteins (CCL15, the human equivalent of CCL9; CXCL7; CRKL) were 
selected to be measured in the plasma of a cohort of 211 allo-HCT recipients previously 
reported.193.  
 
Chemokine neutralizing antibody treatment 
Monoclonal rat anti mouse CCL9 (MAB463), CCL8 (MAB1091) and CXCL7 
(MAB790) were purchased from R&D Systems. To determine whether chemokine 
blockade could reverse cGVHD, cGVHD mice were intraperitoneally injected with 50-
200 µg of each antibody, as indicated, from day 28-56, 3 doses/week. To evaluate the 
effect of anti-CCL9 on the GC reaction induced by sheep red blood cells (SRBCs), mice 
were immunized using SRBCs as described previously194. A cohort of mice was treated 
with anti-CCL9 antibody on days -1, 1, and 3 after immunization. On day 6 post-
immunization, GC reactions were evaluated as above.    
 
Immunohistochemical, immunofluorescence and flow cytometry analysis  
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Mouse lungs were inflated by 75% OCT and embedded in Optimal Cutting Temperature 
(OCT) compound, snap frozen in liquid nitrogen, and stored in -80°C. For trichrome 
staining, 8 µm cryosections were fixed for 15 min in Bouin’s solution at 56°C and stained 
with the Masson’s trichrome staining kit (Sigma HT15). For immunofluorescence 
staining, acetone fixed 8µm cryosections were stained with antibodies against mouse 
immunoglobulin (Ig) (BD 554001), αSMA (ThermoFisher 53-9760-82), CCL9 (Abcam 
ab9913) and CD45 (ThermoFisher 11-0451-82). Splenic GCs were identified using PNA 
(Vector Laboratories). Confocal images were acquired on an Olympus FluoView500 
Confocal Laser Scanning Microscope at 200X, analyzed using FluoView3.2 software 
(Olympus). The collagen deposition area, CD68 and Ig staining were quantified using the 
“color segmentation” plugin of Fiji software. The intensity of CCL9 staining was 
quantified using the “Measure” function of Fiji software.  
 
Flow cytometry analysis of GCs, T follicular helper and T follicular regulatory cells  
To analyze GC reaction, single cell suspension of spleens was obtained and stained with 
fixable viability dye, fluorchrome-labeled anti-CD4 (RM4-5, BD), anti-CXCR5 
(SPRCL5, eBioscience), anti-PD-1 (J43, eBioscience), anti-CD19 (eBio1D3, 
eBioscience), anti-GL7 (GL-7, eBioscience) and anti-Fas (J02, BD). Cells were analyzed 
on BD LSRFortessa. GC B cells were defined as Fas and GL7 double positive CD19+ B 
cells. Follicular helper T (Tfh) cells were defined as PD1 and CXCR5hi CD4+ Foxp3- T 
cells. Follicular regulatory T (Tfr) cells were defined as PD1 and CXCR5hi CD4+ Foxp3+ 
T cells.   
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Patients characteristics 
This study was approved by the Institutional Review Board of the Fred Hutchinson 
Cancer Research Center (FHCRC), and informed consent was obtained from all patients 
or their legal guardians. The cohort of patients has previously been described195. Patient 
and GVHD characteristics for the two groups are presented in Table 1. Briefly, the cohort 
was composed of 211 patients treated at FHCRC from 2008 to 2011. Samples were 
obtained at the time of enrollment on an IRB-approved long-term follow-up study. 
Patients entered this study from 3 months to 66 months post-transplant. The cohort was 
divided into 2 groups: controls without cGVHD (n = 33), patients diagnosed with 
cGVHD (n = 178). 
 
Enzyme-linked immunosorbent assay (ELISA) of human plasma 
Candidate proteins validation was performed with a sequential ELISA protocol196–198. 
Commercial antibody pairs were available for 2 proteins (CXCL17 and CCL15, R&D 
Systems, Minneapolis, MN), and the CRKL kit was customized by Raybiotech, Norcross, 
GA. Elisa was run according to manufacturer’s recommendations. Samples were diluted 
as necessary (CRKL undiluted; CXCL7 1/500; and CCL15 1/25). Lower Limit of 
Quantification (LLOQ), and Upper Limit of Quantification were as followed: CRKL: 1.2, 
50 ng/mL; CXCL7: 15, 1000 pg/mL; CCL15: 15, 1000 pg/mL. Samples and standards 
were analyzed in duplicate as described previously196–198. 
 
Statistics 
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For murine experiments: 
We assumed that the observations came from a normally distributed population as the 
recipient mice are from the same genetic background and the BM and T cells they receive 
are from the same donor. Differences between two groups were compared using two-
tailed unpaired t test using GraphPad Prism software, version 7.02. Error bars in graphs 
represent mean ± standard error of the mean (SEM). Values of p less than .05 were 
considered significant. 
 
For patients: 
Clinical differences in the groups with and without cGVHD were compared with 
Student’s t tests for continuous variables and Fisher’s exact tests for categorical variables. 
Differences of CCL15 raw levels (without log transformation) between patients with and 
without cGVHD were compared using Mann-Whitney test using GraphPad Prism 
software, version 7.02. Error bars in graphs represent mean ± standard error of the mean 
(SEM). Logistic regression was used to evaluate the associations between cGVHD and 
biomarker after log transformation. Differences in cGVHD severity between groups were 
evaluated using the Wilcoxon two-sample tests. The analysis of NRM divided CCL15 
levels at the median value among cGVHD cases and compared cases above and below 
the median. NRM was estimated using cumulative incidence methods, treating relapse as 
a competing risk, and compared between groups using Cox regression. All analyses were 
adjusted for significant clinical variables considering age, sex, stem cell source, 
conditioning (myeloablative vs. others), donor (matched sibling vs. others), and time 
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from HCT to sample collection. All statistical analysis was performed using SAS (Cary, 
NC).  
Results 
Murine cGVHD proteome profiling discovers novel druggable candidate 
biomarkers.  
Using a well-established experimental models of cGVHD29, we performed a proteomics-
based approach using the Tandem Mass Tag™ (TMT) labeling with improvement in the 
workflow used for our recent manuscripts185,193 that includes new depletion column, high 
pH reverse phase separation, and new instrument (shotgun mass spectrometry analysis on 
the Thermoscientific OrbiTrap fusion mass spectrometer on a 2-hour gradient). We 
compared 2 pools of serum in the same proteomic experiment. Pool 1 contained serum 
from 3 mice without cGVHD and pool 2 contained serum from 3 mice with cGVHD, all 
collected on day 56 post-HCT. Each pool contained 100 µl of serum and was labeled with 
a different TMT tag allowing for differential quantification (see details in methods). 
There were three replicates for each pool and analysis was performed as previously185,193. 
885 proteins were identified. Fifty-six proteins were quantified in at least one replicate 
that had a ratio cGVHD/no cGVHD > 1.2 fold increase. Among these 56 proteins, four 
lead candidates (CRKL, CCL8, CXCL7 and CCL9) were selected based those most likely 
to have biological relevance for cGVHD and the availability of murine neutralizing 
antibody or knock-out animals, permitting in vivo cause-and-effect testing. 
 
CRK/CRKL-/- T cells do not cause cGVHD mediated BO  
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CRKL together with CRKI and CRKII belongs to the CRK adaptor proteins family that 
converge and regulate a wide variety of tyrosine kinase pathways based on their protein 
binding domains Src Homology 2 (SH2) and SH3199–201. The role of CRK adaptor 
proteins in GVHD has been recently explored in an acute model188. CKR/CRKL-/- donor 
T cells do not induce acute GVHD but can generate a graft-versus- leukemia (GVL) 
effect, as CKR/CRKL-/- T cells loss the ability of integrin dependent adhesion and 
diapedesis to inflammatory sites; but their homing to lymphoid organs is generally 
intact188.   
 
To study the role of CRK proteins in cGVHD, we transplanted conditioned B10.BR mice 
with BM only or plus wildtype (wt) or CKR/CRKL-/- T cells66. Pulmonary dysfunction 
(indicated by increased pulmonary resistance and elastance and decreased compliance) is 
a hallmark feature of cGVHD in the BO model140 and due to macrophage mediated 
collagen deposition and fibrosis in peribronchial areas24, pathologically linked to Ig 
deposition associated with a GC response66. Mice received BM plus CKR/CRKL-/- T 
cells did not develop cGVHD pulmonary dysfunction as the wt T cells recipients did 
(Figure 1A).  Collagen deposition (Figure 1B) and macrophage infiltration (Figure 1C) in 
peribronchial areas were significantly lower in mice that received CKR/CRKL-/- vs wt T 
cells. In addition, improved survival and significantly increased body weights were seen 
in mice receiving CKR/CRKL-/- T cells (Supplementary figure 1).  
 
		 109	
Previously, we showed that cGVHD mice develop a GC reaction and disrupting the GC 
reaction can ameliorate cGVHD in this model 66. The GC reaction occurs as an result of 
increased Tfh/Tfr ratio and is the immunological hallmark of cGVHD29,66. To study the 
effect of donor T cell CRK/CRKL ablation on GC reaction, splenic GC B cells, Tfh and 
Tfr frequencies were analyzed by flow (Figures 1D-G). Recipients of CRK/CRKL-/- T 
cells have decreased Tfh frequencies (Figure 1D) and a lower Tfh/Tfr ratio (Figure 1F) 
than recipients of wt T cells. Although GC B cell frequencies did not differ at this time 
point  (Figure 1G), Ig deposition in the lung was significantly lower in recipients of 
CRK/CRKL-/- vs wt T cells (Figure 1H). Taken together, these results suggest that 
CRK/CRKL signaling in donor T cells are required for GC reactions and the development 
of cGVHD, suggesting CRK/CRKL can be a therapeutic target. 
 
CCL9 but neither CXCL7 nor CCL8 blockade in vivo reverses established cGVHD 
To determine the potential role of CXCL7, CCL8 and CCL9 in cGVHD pathogenesis, in 
vivo antibody blockade studies were performed. To evaluate the therapeutic role of 
blocking each chemokine, cGVHD mice were given each antibody intraperitoneally 
starting from day 28, when lung dysfunction is readily evident, to the end of each 
experiment. Neutralizing antibody (100 µg/dose) to CCL8 did not affect cGVHD. 
Neutralizing antibody (100 µg/dose) to CCL7 showed a trend toward disease reduction. 
However increased CXCL7 antibody dose (200 µg) did not improve the effect but 
resulted in similar pulmonary function as non-treated mice (Figure S2). CCL9 blockade 
at a lower dose (50 µg) incompletely reduced the lung disease (data not shown), while an 
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increased dose at 100 µg significantly improved each pulmonary function parameters 
(Figure 2A). Survival and weight of anti-CCL9 treated mice were also slightly improved 
(Figure S3). 
 
CCL9 and its human analogue CCL15 are well-recognized for its role in wound 
healing202.  Therefore, we examined collagen deposition in the lung by trichrome 
staining. CCL9 blockade significantly reduced collagen deposition in lung compared to 
non-treated cGVHD mice (Figure 2B). CCL9 also plays important role in the chemotaxis 
of innate myeloid suppressor cells203–205 and adaptive immune cells such as CD4 and 
CD8 T cells 206–208. Thus we sought to determine whether CCL9 blockade has an effect 
on macrophage infiltration into the lungs of cGVHD mice, which has been proven to 
participate cGVHD pathogenesis24,26. CCL9 blockade significantly reduced macrophage 
infiltration compared to cGVHD controls (Figure 2C). CCL9 blockade also significantly 
reduced Ig deposition in the lung (Figure 2D), and splenic GC B cells and Tfh 
frequencies along with the Tfh/Tfr ratio (Figure 2E-H).  .  
 
Spleen vascular smooth muscle cells and lung increase CCL9 expression during 
cGVHD 
To determine the cellular source that contributed to increased serum CCL9 concentrations 
in cGVHD, we examined the expression of CCL9 in the spleen, the site of the GC 
response. CCL9 expression is significantly higher in cGVHD mice than in BM only mice 
(Figure 3A). However, neither CD11b myeloid cells nor cells in the GCs were the main 
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source of CCL9 (Figure 3A). Instead, CCL9 was dominantly expressed in the vasculature 
(Figure 3A), but not in hematopoietic cells that express CD45 (Figure S4A). To further 
explore the cell types that produce CCL9 during cGVHD, we co-stained CCL9 with 
smooth muscle marker α smooth muscle actin (αSMA) (Figure 3B) and endothelial cell 
marker CD31 (Figure S4B). CCL9 was mainly produced by smooth muscle cells (SMCs) 
but not endothelial cells in cGVHD mice.  CCL9 expression in splenic SMCs was only 
seen in cGVHD mice but not BM only mice (Figure 3B), suggesting CCL9 expression 
may be induced by allo-responsive donor T cells. Blockage CCL9 using monoclonal 
antibody did not alter the expression level or pattern of CCL9 expression on SMCs, 
suggesting anti-CCL9 antibody blocked the function, rather than expression of CCL9.  
 
Having shown that CCL9 is increased in the spleens of cGVHD mice and CCL9 is 
expressed in higher amounts at sites of vasculature, we next sought to determine whether 
increased CCL9 expression in splenic GCs is uniquely induced in cGVHD, or this is a 
common mechanism during GC reactions.  Naïve mice were immunized with SRBCs to 
induce GC reactions and treated with anti-CCL9 antibody (100 microgram) on days -1, 
+1, and +3. CCL9 staining suggests that in the vessel areas of the SRBCs immunized 
spleens, CCL9 expression was not increased as in cGVHD mice (Figure S5A). GC B 
cells and Tfh cell frequencies were unaltered by CCL9 blockade (Figure S5B), in 
accordance with lack of increased CCL9 expression in spleen SMCs. This result suggests 
that CCL9 expression in the vascular SMCs is uniquely induced during cGVHD and 
targeting this unlikely affect antibody responses.  
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A recent study suggested angiogenesis happens early after allo-HSCT, and play an 
important role in initiating acute GVHD209. Since SMCs are a major cellular component 
of the vascular wall, we explored whether cGVHD has higher SMCs volume.  We 
quantified αSMA and found that cGVHD spleens have significantly higher αSMA 
staining areas than BM only mice, suggesting neoangiogenesis may be associated with 
cGVHD. Increased smooth muscle volume was not altered by CCL9 blockade (Figure 
S6), suggesting CCL9 acts downstream of increased SMCs during cGVHD pathogenesis.  
We further examine CCL9 expression in the lung, where fibrosis occurs as a result of GC 
reaction and macrophage activation.  Different from the BM only splenic SMCs with 
barely detectible CCL9, BM only lungs express low level of CCL9, mainly by the lung 
bronchiolar wall (Figure 3C). This expression is increased during cGVHD, but not altered 
by CCL9 antibody blockade (Figure 3C). Together, these results suggest that during 
cGVHD CCL9 expression is specifically induced in splenic SMCs and increased in lung, 
and that the effect of blocking antibody on cGVHD is likely due to blockade of CCL9 
chemotaxis function (Figure 3D).  
 
CCL15, the human homologue of murine CCL9, is a predictive biomarker for 
cGVHD incidence and NRM in a well-defined patient cohort.  
CCL9 blockade and CRK/CRKL deficiency of donor T cells significantly ameliorated 
mouse cGVHD. Therefore, we sought to determine the relevance of CCL9 and CRKL as 
biomarkers in human plasma by comparing patients with and without cGVHD. We also 
tested CXCL7 to confirm the strength of our workflow focusing on mechanistically 
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relevant and druggable markers. We measured the concentrations of these 3 proteins in 
samples from well-defined cohorts, consisting of 178 HCT patients with cGVHD and 33 
HCT controls without cGVHD. We also measured the proteins in 15 healthy donors as 
baseline values. Patient and GVHD characteristics for the two groups are presented in 
Table 1. Patient sex and median age at the time of transplantation were similar between 
the two groups. There was a trend toward over-representation of unrelated donors in the 
cGVHD group. As expected, the use of peripheral blood stem cells (PBSCs) was a risk 
factor for cGVHD, whereas the use of full-intensity conditioning was not. The incidence 
of prior aGVHD was similar in both groups. According to the NIH global severity score, 
7% of the patients had mild cGVHD, 58% had moderate cGVHD, and 35% had severe 
cGVHD. Plasma samples were collected at similar times from both cGVHD patients and 
controls: a median of 391 days (192–1852 days) post-HCT in the cGVHD group 
compared to 369 days (161–3641 days) post-HCT in the control group (p=0.84).  
As hypothesized based on the murine cGVHD data, there was no significant difference in 
CXCL7 levels between patients with and without cGVHD (data not shown). Using a 
customized CRKL1 ELISA kit > 95% of the plasma values were below the detection 
level of 1.2ng/ml even when using undiluted plasma. Thus, we have no evidence of 
CRKL1 elevation in cGVHD patients.  
 
In contrast, CCL15 concentrations were significantly increased in cGVHD patients as 
compared to patients following allo-HCT without cGVHD, p=0.0125 (Figure 4A). We 
next evaluated whether CCL15 was associated with cGVHD severity.  Very few patients 
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had mild cGVHD, and thus, these patients were combined with those who presented with 
moderate cGVHD. CCL15 was log-transformed and logistic regression was used to 
evaluate its association with cGVHD. Analyses of CCL15 were adjusted for the 
following seven clinical variables: age, sex, donor (matched sibling vs. others), stem cell 
source (PBSC vs. others), conditioning intensity (myeloablative vs. others), prior 
aGVHD, and time from HCT to sample collection. Notably, only donor type (p=0.03) and 
PBSCs as the stem cell source (p=0.01) were significant in multivariate analysis. Using 
Wilcoxon two-sample tests, we compared CCL15 between groups with different cGVHD 
severity (none, mild/moderate, and severe). The differences of CCL15 between the two 
severity groups and controls are statistically significant (p=0.02 and p=0.03, respectively) 
but not between the severity groups (p=0.99), (Figure 4B). cGVHD patients with CCL15 
values above the median were at higher risk of NRM than patients with low CCL15 
levels [Hazard Ratio (HR)=2.89 (1.1-7.4), p=0.03, (Figure 4C). Altogether, these data 
suggest that CCL15 represents a clinically relevant biomarker as well as a druggable 
biomarker with in vivo activity.  
 
Discussion 
Using high throughput, discovery-based Mass Spectrometry (MS) technique, we 
conducted full spectrum proteomic analysis of serum samples from a well-established 
murine multi-organ system cGVHD model and identified 56 differentially expressed 
proteins, 4 of which were potential biomarkers of cGVHD. We identified two biomarkers, 
CRK/CRKL and CCL9, that were shown to be essential for inducing and maintaining 
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murine cGVHD. Of these, the human homologue of CCL9, CCL15, was found to be 
increased in cGVHD patient plasma and correlated with NRM rate, suggesting that 
CCL15 may serve as a potential biomarker for cGVHD early diagnosis and therapy.  
cGVHD patients have very limited treatment therapies. Targeting CCL9 in the mouse 
model reversed cGVHD clinical manifestations and restored immunological balance, 
which was disturbed during cGVHD. Of interest, blocking RANTES (CCL5), which is 
increased in the lung after allo-HSCT210 and shares the same receptor CCR1 with CCL15, 
has been shown to alleviate acute GVHD211, suggesting that CCL15 may be useful as a 
biomarker and potentially as a therapeutic target in patients with concurrent acute and 
chronic GVHD.  
CCL15 is produced in a wide variety of tissue and cell types212 in steady state and is 
increased in autoimmune diseases such as rheumatoid arthritis213 and asthma214. Similar 
to CCL15, CCL9 is expressed constitutively in tissues and cells including both 
hematopoietic and non-hematopoietic origin. CCL-9 produced by structural cells such as 
follicle associated epithelium207,  airway smooth muscle215 and lung endothelial cells216 
play roles in recruiting dendritic cells and monocytes and contribute to disease 
pathogenesis. In this study, we show uniquely increased CCL9 expression in cGVHD 
spleens in the αSMA positive vascular SMCs areas but not in CD11b myeloid cells or 
CD45 hematopoietic cells, highlighting a previously unappreciated role of vascular 
SMCs in cGVHD pathogenesis. Vascular SMCs can be converted into chemokine-
expressing cells that trigger the recruitment of immune cells in response to inflammatory 
signals217,218. Increased spleen SMCs CCL9 expression during cGVHD is not due to pre-
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transplantation conditioning or a consequence of germinal center reaction, as neither BM 
only recipients nor SRBC immunized mice display this pattern, highlighting CCL9 
increase is a specific mechanism to meet the need of increased GC reactions during 
cGVHD and can be a target for cGVHD therapy. A recent study suggests neo 
angiogenesis occurs early after allo-HCT that proceeds inflammation and play a active 
role in the initiation of acute GVHD209. We identified that SMCs - the major cellular 
component of vascular wall were also increased in spleen during cGVHD.  Thus 
increased CCL9 expression in cGVHD spleen was a combined effect of increased SMCs 
volume and increased CCL9 expression from SMCs. To identify potential cell 
populations recruited by CCL9 in spleen, we co-stained CD11b, CD4 and CD68 but did 
not find a positive correlation (data not shown). Thus the cells being recruited by CCL9 
in spleen can be heterogenic. 
Increased CCL9 was also noticed in cGVHD lungs and blocking CCL9 reduced 
macrophage infiltration, collagen deposition and improved pulmonary function. 
Previously we reported that macrophages infiltrate the cGVHD lung and contribute to 
cGVHD pathogenesis by producing TGF-β24. Thus reverse of cGVHD by CCL9 
blockade is at least partially due to blocking macrophage chemotaxis by the CCR1/CCL9 
axis. Thus we hypothesize the during cGVHD, splenic SMCs and lung bronchiolar wall 
are activated by allo-responsive donor T cells to recruit cells for GC reactions in spleen 
and macrophages in lung, thus blocking CCL9 function by CCL9 antibody reverse 
cGVHD (Figure 3D).  
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Although CXCL7 and CCL8 levels were increased in cGVHD sera, blocking neither of 
them showed benefit to cGHVD.  Both CXCL7 and CCL8 can be produced in response 
to inflammatory stimuli and exert chemotactic functions towards neutrophils and Th2 
cells, respectively219,220.  We hypothesize the CXCL7 and CCL8 was produced as a result 
of tissue damages caused by pre-transplantation conditioning and donor T cell allo-
responses.  However, CXCL7 and CCL8 may not directly involve in cGVHD 
pathogenesis based upon neutralizing antibodies results. In addition, plasma CXCL7 was 
not increased in cGVHD patients, in accordance with lack of treatment effect by CXCL7 
blockade on murine model. We did not test CCL8 in human plasma both due to its total 
lack of cGVHD inhibition and its elevation in several inflammatory and tumoral diseases 
lacking specificity as a possible cGVHD plasma marker. CRK/CRKL are intracellular 
adaptors proteins that can regulate immune responses221. Both our mice proteomics data 
and a previous report201 suggest CRK/CRKL can be secreted into the extracellular milieu. 
However, the circulating levels of CRK/CRKL in patient plasma were below the 
detection limit when measured by Elisa and therefore definitive conclusions cannot be 
made on its potential role as a biomarker until more sensitive ELISAs become available.   
 
In summary, we conducted for the first time full-spectrum proteomic analysis of a well-
characterized murine model of cGVHD as a novel discovery engine for potential cGVHD 
biomarkers that could be translated into the clinic. This has led to the identification of 2 
druggable candidate biomarkers, of which the human homologue of CCL9, CCL15, was 
verified in a previously published cGVHD cohort of 211 HCT patients. This study 
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highlighted the potential of CCL9/CCL15 as a biomarker for cGVHD early diagnosis and 
prediction of NRM, both unmet need yet crucial for cGVHD management, and as a 
treatment target. Further validation on larger independent cohort is warranted.  
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Table 1: Patient and cGVHD characteristics  
 
  
		 121	
Figures legends  
Figure 1: CRK/CRKL-/- T cells do not cause cGVHD mediated BO 
Conditioned B10.BR mice were transplanted with B6 donor BM only, or plus 70000 wt 
or CRK/CKRL-/- T cells. (A). Pulmonary tests including lung resistance, elastance and 
compliance suggest CRK/CKRL-/- donor T cells did not cause cGVHD. (B). Masson’s 
Trichome staining in lung identified collagen in blue. Quantification of blue areas 
suggests recipients of CRK/CKRL-/- donor T had significantly lower collagen deposition 
the wt T cell recipients. (C). Immunofluorescence staining of macrophage marker CD68 
suggests significantly lower macrophage infiltration in the CRK/CRKL-/- T recipients. 
(D-G). Flow cytometry analysis of cell frequencies in GC reactions including Tfh (D), 
Tfr (E), Tfh/Tfr ratio (F) and GC B cell (G). GC analysis suggest CRK/CKRL-/- donor T 
cells did not induce GC reactions. (H) Immunofluorescence staining of Ig deposition in 
the lung. Quantification suggests recipients of CRK/CKRL-/- donor T cells have lower Ig 
deposition. Images were taken by Olympus FV1000 upright confocal at 200x 
magnification. Data shown are representative of 2 independent experiments with 5-8 
mice per group. Unpaired student T-test was used when comparing 2 groups.  
Significance: *P<0.05; **P<0.01; ***P< 0.001; ****P<0.0001. 
 
Figure 2: CCL9 blockade reverses cGVHD clinical manifestations and 
immunological hallmark  
Transplanted mice were treated with anti CCL9 (100mg) from day28 post bone marrow 
transplant. Experiments were terminated at day 42-56. (A). Pulmonary function tests 
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suggest CCL9 blockade reverse cGVHD lung disease. Collagen deposition (B), 
macrophage infiltration (C) and Ig deposition (D) were significantly reduced by CCL9 
blockade. (E-H). Splenic GC reactions analysis. Frequency of GC B Cells (E), Tfh (F) 
and Tfh/Tfr ratio (H) were normalized by CCL9 blockade. Data shown are representative 
of 2-3 independent experiments with 5-8 mice per group. Unpaired student T-test was 
used when comparing 2 groups.  Significance: *P<0.05; **P<0.01; ***P< 0.001; 
****P<0.0001. 
 
Figure 3: Spleen vascular smooth muscle cells and lung increase CCL9 expression 
during cGVHD 
(A). Immunofluorescence staining (200 x magnification) of spleen sections of BM only 
and cGVHD mice.  White arrow indicates CCL9 was dominantly expressed by spleen 
vasculature, but not CD11b cells or cells in the GC areas. Quantification of CCL9 
staining areas suggests cGVHD mice have increased CCL9 expression in spleen. (B). 
Costaining of αSMA with CCL9 in the spleen. Images were taken at 400x magnification. 
αSMA positive cells of cGVHD mice had increased CCL9 expression that was not altered 
by CCL9 blockade. Images were quantified by Fiji software “color segmentation” plugin. 
(C). CCL9 expression in lung. Quantification was done by Fiji software “measure” 
function. Data shown are representative of 2-3 independent experiments with 5-8 mice 
per group. Unpaired student T-test was used when comparing 2 groups.  Significance: 
*P<0.05; **P<0.01; ***P< 0.001; ****P<0.0001. (D) Possible mechanism by which 
CCL9 contributes to cGVHD pathogenesis. 
		 123	
Figure 4: Increased CCL15 levels are associated with high non-relapse mortality 
rate but not disease severity 
(A) Plasma concentrations of CCL15 was measured by ELISA in a cohort of 178 cGVHD 
patients, 33 no cGVHD transplant recipients and 15 healthy donors. Differences of 
CCL15 levels between patients with and without cGVHD were compared with Wilcoxon 
two-sample tests. CCL15 concentration was significantly higher in cGVHD patients as 
compared to no cGVHD. (B) cGVHD patients were sub-categorized into 2 groups based 
on severity of disease. Data are illustrated as box and whisker plots, with the whiskers 
indicating the 90th and 10th percentiles. P values compare controls (n=33) versus patients 
with mild to moderate cGVHD (n=116), and patients with mild to moderate cGVHD 
versus those with severe cGVHD (n=62), according to Wilcoxon two-sample tests. 
CCL15 levels were not different between severity groups. (C) Nonrelapse mortality 
(NRM) stratified by CCL15 concentrations. The cumulative incidence of NRM is plotted 
(total of 21 NRM deaths), divided according to the median value of CCL15 among 
patients with cGVHD. The NRM at 48 months was higher for the group above the 
median value [Hazard Ratio (HR) = 2.89 (1.1-7.4), P = 0.03].  
 
Figure S1. CRK/CRKL-/- donor T cells result in improved survival and significantly 
higher body weight 
Survival and weight were recorded after transplantation. CRK/CKRL-/- donor T recipients 
had 100% survival versus 75% in wt T recipients, which were not significantly different. 
At periodic time points, mean weights were significantly higher in CRK/CKRL-/- vs wt 
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donor T recipients. Data shown are representative of 2 independent experiments with 5-8 
mice per group. Unpaired student T-test was used when comparing 2 groups.  
Significance: *P<0.05; **P<0.01; ***P< 0.001; ****P<0.0001. 
 
Figure S2: Neutralizing CXCL7 or CCL8 did not affect cGVHD 
Transplanted mice were treated with anti CXCL7 (100mg or 200mg/dose) or CCL8 
(100mg/dose) from 28-56 days post bone marrow transplant. Pulmonary function test 
suggest neither anti-CXCL7 nor anti-CCL8 significantly altered cGVHD lung disease. 
Unpaired student T-test was used when comparing 2 groups.  Significance: *P<0.05; 
**P<0.01; ***P< 0.001; ****P<0.0001. 
 
Figure S3 Anti-CCL9 treatment slightly improve survival and weight of cGVHD 
mice. 
Survival and weight were recorded after transplantation. Anti-CCL9 treatment group had 
100% survival versus cGVHD group 80%. No significant differences were seen in weight 
curves.  
 
Figure S4: Neither CD45 hematopoietic cells or CD31 endothelial cells are the main 
producers of CCL9 in cGVHD spleen 
(A). Staining of CD45 and CCL9 in spleen suggest hematopoietic cells were not the main 
producers of CCL9 during cGVHD. Images were taken at 200 x magnification. (B) CCL9 
		 125	
and CD31 staining did not co-localize suggesting CD31 endothelial cells were not the 
source of CCL9. Images were taken at 200 x magnification. 
 
Figure S5: CCL9 did not involve in SRBC induced GC response 
Naïve B6 mice were immunized by 100 microliter of 10% SRBC. CCL9 (100mg) was 
given on days -1, +1, and +3 of immunization. Mice were sacrificed on day 6. (A) 
Immunofluorescence staining of spleen sections suggests CCL9 was not increased in 
SRBC immunized mice. Images were taken at 200 x magnification (B) Flow cytometry 
analysis of GC reactions suggests anti-CCL9 antibody had not effect on SRBC induced 
GC reactions. Unpaired student T-test was used when comparing 2 groups.  Significance: 
*P<0.05; **P<0.01; ***P< 0.001; ****P<0.0001.  
 
Figure S6: cGVHD mice have higher vascular SMCs volume that was not altered by 
anti-CCL9 antibody.  
Immunofluorescence staining of αSMA in spleen at 100 x magnfication. cGVHD group 
had significantly higher aSMA positive areas than BM only group, which was not altered 
by anti-CCL9 treatment. Data shown are representative of 2 independent experiments 
with 5-8 mice per group. Unpaired student T-test was used when comparing 2 groups.  
Significance: *P<0.05; **P<0.01; ***P< 0.001; ****P<0.0001.	
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Chapter 6 Concluding Statements   
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The application of aHSCT is mainly hindered by GVHD in spite of advances in clinical 
practice. cGVHD in specific remains the prevailing cause of nonrelapse mortality in 
long-term survivors of aHSCT. The current standard therapy for cGVHD is broad 
immune suppressive agents that may contribute to infection and relapse. New therapies 
are needed although there have been relatively few advances in the clinical management 
over several decades. With the development of several newer murine models of cGVHD 
that mimic different aspects of human cGVHD, the understanding of the pathogenesis of 
cGVHD has been significantly increased. In this study, we built on the current known 
knowledge of cGVHD mechanisms and evaluated several mechanistic approaches in 
preventing and treating cGVHD. Using different pre-clinical murine models of cGVHD 
we have identified new mechanisms of cGVHD and several potential therapeutic targets 
that might be brought into the clinic. 
  
cGVHD is known to be a complex immune reaction rather than an extension of acute 
GVHD that was previously thought. A 3 phase model has been proposed that involved 
inflammation and tissue injury leading to donor T cell activation and effector function 
(phase 1), dysregulated immunity with auto immune phenotype (phase 2), and aberrant 
tissue repair often with fibrosis (phase 3). In the second chapter of this study, we 
described targeting a Ca2+ dependent inositol triphosphate kinase Itpkb using both genetic 
deletion and pharmaceutical inhibition could block cGVHD. This study suggested Itpkb 
is important in T cell alloresponse as Itpkb-/- donor T cells could not cause cGVHD. 
Interestingly, lack of this enzyme in BM did not seem to affect the development of 
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cGVHD. From the previously published studies, it is known that cGVHD is initiated by 
donor T cells in the graft and sustained by donor BM derived T cells and B cells. The 
different outcomes of Itpkb depletion on donor T cells and BM suggested Itpkb function 
is specifically required during allo-responses. Pharmaceutical inhibition of Itpkb using a 
selective low molecular weight compound GNF362 led to decrease of cGVHD in both 
the BO model and the scleroderma model. This study highlighted that blocking T cell 
function using LMW inhibitors early after aHSCT might be promising in ameliorating 
cGVHD. The initiating stages of acute and chronic GVHD have overlapping mechanism 
and depend largely on donor T cells. It is of interest to know whether blocking Itpkb has a 
role in aGVHD. In addition, future study should address the effect of GNF362 on 
infection and tumor.  
 
The second stage of cGVHD is characterized by disrupted immune effector/regulatory 
balances thus the autoimmune phenotype in patients. Lack of regulatory subsets of 
immune cells such as Treg has been implicated in cGVHD. In the third chapter of this 
study, we reported an inadequate iNKT pool in cGVHD mice and the disrupted immune 
balance in cGVHD can be corrected by infusing iNKT- a small subset of T lymphocytes 
with potent immune regulatory functions. Therapeutic effect of iNKT is associated with 
an increased Treg density in the GC areas. Infused iNKT expand Treg through an IL-4 
and CXCR5 dependent mechanism. This is of significant clinical relevance as iNKT has 
been show to reduce aGVHD, which is a risk factor for cGVHD. The shared effect of 
iNKT in both acute and chronic offers the possibility for optimal treatment of patients 
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with dual acute and chronic GVHD components. Compared to Treg, iNKT infusion offers 
several clinical advantages such as that iNKT can reach similar therapeutic effect with 
much fewer cells and that iNKT is more stable in function. We further demonstrated the 
efficacy of RGI2001, a peptide that activate iNKT cells in vivo after administration in 
preventing and treating cGVHD. This study offered an alternate immune regulation 
strategy to cGVHD patients.  
 
Disrupted immune balance leads to antibody mediated tissue fibrosis, which often marks 
the end stage of cGVHD biology. Fibrosis in lung and skin leads to progressive BO and 
scleroderma and are the most detrimental and treatment refractory forms of cGHVD. 
Thus, in the fourth chapter of the study, we evaluated an anti-fibrosis agent that has been 
approved by FDA for the treatment of idiopathic pulmonary fibrosis. We discovered that 
pirfenidone reversed cGVHD though inhibition of macrophage infiltration and TGF-β 
production. Using an intravascular staining technique, we showed that the both 
macrophages and alveolar macrophages have increased production TGF-β – a pivotal 
cytokine for fibrotic responses. This study highlight the role of macrophage in cGVHD 
pathogenesis. Pirfenidone inhibited GC reaction in cGVHD but had no effect on GC 
responses in SRBC immunized mice. This suggests that pirfenidone reduces cGVHD GC 
responses by reducting the autoangen – collagen.  We hypothesize a feedback loop may 
exist in cGVHD pathogenesis where GC reaction lead to Ig and collagen deposition, and 
collagen can serve as autoangen to fuel GC reactions. In addtion, we show that that 
pirfenidone administration at a later stage of disease is still very effective at reducing BO. 
		 140	
This novel finding is extremely important as there is an option of administering 
pirfenidone intermittently for patients who cannot tolerate continuous dosing without 
compromising drug efficacy.  These data support the use of pirfenidone as a new agent in 
early-phase clinical trials for cGVHD treatment. 
 
In the last part of this study, we focused on discovery and validation of novel druggable 
biomarkers for cGVHD. Using a whole serum proteomics analysis of a well-established 
murine multi-organ system cGVHD model, we discovered 4 up-regulated proteins during 
cGVHD that are targetable by genetic ablation or blocking antibodies, including the RAS 
and JUN kinase activator, CRKL, and CXCL7, CCL8 and CCL9 chemokines. Donor T 
cells lacking CRK/CRKL prevented the generation of cGVHD, germinal center reactions 
and macrophage infiltration seen with wild-type T cells. Whereas antibody blockade of 
CCL8 or CXCL7 was ineffective in treating cGVHD, CCL9 blockade reversed cGVHD 
clinical manifestations, histopathological changes and immunopathological hallmarks. 
Mechanistically, elevated CCL9 expression was present predominantly in spleen vascular 
smooth muscle cells and uniquely seen in cGVHD mice. Importantly, plasma 
concentrations of CCL15, the human homologue of mouse CCL9, were elevated when 
analyzed in a previously published, well-defined cohort of 211 cGVHD patients 
compared to controls. High CCL15 levels were associated with high NRM. These 
findings demonstrate for the first time the utility of preclinical proteomics screening to 
identify potential new targets for cGVHD and specifically CCL15 as a marker for 
cGVHD diagnosis.  
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In summary, this dissertation addressis the fundamental questions about cGVHD 
therapies and identified several potential therapeutic targets including Itpkb enzyme, 
CRKL/CRK adaptor proteins and CCL15, several componds with therapeutic efficacy 
including GNF362, RGI2001 and pirfenidone, and  a potential biomarker – CCL9. This 
study also shed light on several previously unknown mechanisms of cGVHD 
pathogenesis.   
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Figure 1. Blocking cGVHD at different biological stages 
A 3-step model for the initiation and development of chronic GVHD is proposed that 
involves tissue injury (phase 1), dysregulated immunity (phase 2), and aberrant tissue 
repair and fibrosis (phase 3). In phase 1, factors such as irradiation, chemotherapy and 
previous aGVHD result in tissue damage and release of inflammatory cytokines – leading 
to the activation of donor T cells.  Depletion of Itpkb or CRKL in donor T cells 
completely blocked aGVHD (Chapter 2&5). Phase 2 is characterized by lost of tolerance 
mechanism and autoimmune reactions. This stage is characterized by increased GC 
responses as a result of disturbed Tfh/Tfr, increased BAFF/B ratio, and an inadequate 
iNKT role. These factors lead to Ig deposition in cGVHD target organs. The balance of 
effector and regulatory function can be restored by iNKT infusion and CCL9 blockade 
(Chapter 3&5). In Phase 3, tissue damage caused in phase 1 and Ig deposition caused in 
phase 2 trigger tissue repair and pro-fibrotic pathways such as M2 macrophage activation 
and TGF-β production, leading to uncontrolled tissue repair and organ fibrosis. This can 
be reversed by anti-fibrotic treatment such as Pirfenidone (Chapter 4).   
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